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DAPK-1 is calcium-calmodulin regulated protein kinase involved in multiple cellular 
pathways including apoptosis, autophagy, cell survival and motility. The cytokine 
TNF- has been reported to induce the degradation of DAPK-1. Here I identified the 
protease cathepsin B as a novel binding partner of DAPK-1 that protects DAPK-1 
from TNF- induced degradation. Using deletion mutants of DAPK-1, I mapped the 
cathepsin B binding domain on DAPK-1 to amino acids 836-947. Overexpression of 
this mini-protein DAPK-1(836-947) facilitated degradation of full-length DAPK-1 
and apoptosis induced by TNFR-1. Moreover, siRNA mediated knock-down of 
DAPK-1 enhanced TNF- induced apoptosis, confirming the role of DAPK-1 as a 
survival factor in the TNF- signalling pathway.  
 
In addition, a splice variant of DAPK-1, which I have called s-DAPK-1, was 
discovered. s-DAPK-1 shares part of DAPK-1’s ankyrin repeats region and 
cytoskeletal binding domain, and possesses an unique tail region, which contains a 
cleavage site at its first two amino acids. Unlike DAPK-1, s-DAPK-1 does not 
contribute to apoptosis induced by high level of MEK/ERK signalling, but it does 
mimic DAPK-1’s function to induce membrane blebbing. The proteolytically 
processed form of s-DAPK-1 is more active in the induction of membrane blebbing, 
which may be due to its higher stability compared to that of full-length s-DAPK-1, 
suggesting that the tail region can control s-DAPK-1 stability and activity.  
 
 VII
Co-transfection of s-DAPK-1 and DAPK-1 leads to reduction in DAPK-1 expression 
level, suggesting a role for s-DAPK-1 to regulate DAPK-1 stability. The kinase 
domain of DAPK-1 is the region required for s-DAPK-1 to promote DAPK-1 
degradation. Surprisingly, s-DAPK-1 does not bind directly to DAPK-1, suggesting 
that the interaction is indirect and mediated by as yet unidentified accessory proteins. 
Finally, the experiments with proteasome and lysosome inhibitors indicated that s-
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Chapter One Introduction 
1.1 Cancer, cell cycle and cell death  
Cancer kills several million people every year. It is caused by disorders of cell 
growth or cell death pathways, which give rise to uncontrolled cell proliferation 
resulting in tumours1. In normal cells, the cell cycle is the process by which cells 
grow, replicate their DNA and then divide into two daughter cells2.  It consists of cell 
growth phase G1, DNA replication phase S, division preparation phase G2, mitosis 
phase M and a post-mitosis quiescent phase G0 (Figure 1.1)2. At the boundary of 
G1/S and G2/M phases, there are cell cycle checkpoints that ensure the fidelity of 
cell division. Therefore when mistakes like DNA damage are detected, cells are 
arrested at these checkpoints to allow for DNA damage to be repaired. If the damage 
can not be repaired, the cells are targeted for destruction by programmed cell death 
(PCD), which is an intrinsic cell suicide process that is regulated by a variety of 
cellular signalling pathways3.  
 
Mutation of genes involved in the regulation of cell proliferation or death are 
common molecular mechanisms underlying formation of tumours. The genes that 
facilitate the growth of tumours are called oncogenes, while those that inhibit tumour 
growth are called tumour suppressor genes. Many oncogenes and tumour suppressor 
genes have been identified. Discovery of these genes allows the study of cancer at 
the molecular level and provides many potential drug targets for more tailored cancer 
treatment compared to surgery, chemotherapy or radiotherapy. For example, the 
tumour suppressor gene p53 can induce cell cycle arrest and apoptosis in response to 
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DNA damage4 and is mutated in more than 50% of human cancers5.  Naturally p53 is 
an important drug target and more than 40,000 papers have been published 
concerning this gene.  
 
Gene mutation is the major mechanism for tumourigenesis, however tumour cell 
survival is also regulated in vivo by cytokines, which are small proteins secreted by 
cells that mediate cell-cell communications via cytokine receptors at the surface of 
neighbouring cells to induce a variety of signalling pathways6. Cytokines that are 
secreted in response to infection, inflammation and immunity can function to inhibit 
tumour development and progression. On the other hand, cancer cells can respond to 
host-derived cytokines that promote growth, attenuate apoptosis and facilitate 
invasion and metastasis. Many cytokines have been discovered, including 
Interleukins (IL), lymphokins, Tumour Necrosis Factors (TNF), Tumour Growth 
Factors (TGF) and Interferons (IFN). Because of their potent effects to induce cell 
death, cytokines like TNF- and IFN- have been widely used in cancer research to 
study the signalling pathways regulating cell death6.  
 
1.2 Discovery and structure of DAPK-1 
In 1995, a functional screen based on random knockdown of gene expression was 
carried out in order to search for new genes involved in cell death7. In this screen, 
Hela cells were transfected with an antisense cDNA library, and then clones that 
could survive the continuous exposure to cytotoxic signals induced by IFN- were 
selected. Isolation and characterization of cell death-protective antisense cDNA 
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fragments within the selected clones led to the discovery of a group of cell death 
related genes. One of the genes isolated is transcribed into a single 6.3kb mRNA, that 
is translated into a 160kDa protein kinase, named Death Associated Protein Kinase 1 
(DAPK-1).  
 
In 1997, DAPK-1 was identified as a calcium/calmodulin (Ca2+/CaM)-dependent 
serine/threonine kinase with cell death inducing functions. DAPK is a multi-domain 
protein. In addition to its kinase domain and CaM regulatory domain, DAPK-1 
contains an ankyrin repeats region consisting of 8 repeats, two P-loops (Phosphate 
binding loop), a cytoskeletal binding domain, a C-terminal death domain and a 17 
amino acids (aa) tail rich in serine residues (Figure 1.2)8. The ankyrin repeat is a 
33aa motif in proteins that mediates protein-protein interactions9. The P-loop is a 
nucleotide ATP/GTP binding motif found in many proteins10. The cytoskeletal 
binding domain, as its name indicates, mediates the interaction between proteins and 
the cytoskeleton11. The death domain is a conserved stretch of around 80aa, which is 
a commonly found in death receptor proteins, and acts as a protein interaction 
domain and a platform for death-inducing signalling complex (DISC) formation12. 
The serine-rich tail is a common feature for death domain containing proteins and 
possesses an inhibitory effect towards DAPK-1 activity13, 14.  
 
DAPK-1 plays a role in multiple cellular signalling pathways including apoptosis, 
autophagy, membrane blebbing and cell movement (see Section 1.8 for details). A lot 
of work has focussed on identifying novel interactive partners of DAPK-1.  By 
examining DAPK-1 functional domains in isolation a number of DAPK-1 interactive 
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proteins have been identified (see Section 1.7 for details). Regulation of DAPK-1 
activity and expression has also been intensively studied and has revealed that  
DAPK-1 is regulated at the transcriptional level as well as post-translationally by 
phosphorylation and ubiquitin-mediated degradation (see Section 1.9 for details).   
 
1.3 DAPK-1 family members 
DAPK-1 shows significant homology in its catalytic domain to those of another 4 
kinases, i.e. DRP-1 (DAPK-1 related protein 1, also named DAPK-2), ZIP kinase 
(Zipper interacting kinase, also named DAPK-3), DRAK1 (DAPK-1 related protein 
1) and DRAK215. DRP-1 and ZIP kinase share around 80% homology in the catalytic 
domains to that of DAPK-1, while DRAK1 and DRAK2 share approximately 50% 
(Figure 1.2). However, the extra-catalytic domains of these five proteins are 
markedly different from each other. Only DRP-1 possesses a CaM regulatory domain 
like DAPK-1. ZIP kinase contains a leucine zipper motif, and the C-terminal regions 
of DRAK1 and DRAK2 don’t show any known structural homology to other proteins. 
Because of the high similarities in the kinase domains, DAPK-1, DRP-1 and ZIP 
kinase are usually grouped into one superfamily. They share similar substrate 
preference and overlap partially in biological functions15. But the difference in the 
extra-catalytic domains of these superfamily members also confers unique functions 
for each of them. For instance, the leucine zipper motif of ZIP kinase mediates its 
dimerization and interaction with transcription factor ATF4 and the apoptosis 
antagonizing transcription factor (AATF)16. As the prototypic member of this family, 
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DAPK-1 has been extensively studied and reported to be involved in various cellular 
signalling pathways.  
 
Interestingly, an alternative spliced isoform of DAPK-1 named DAPK-1, which 
possesses a unique 12aa extension following the ser-rich tail, was identified in both 
mouse and human cells17, 18. It has been shown that this isoform functions differently 
from DAPK-1 to antagonize apoptosis17. However this observation is controversial 
because independent groups of researchers demonstrated that DAPK-1’s function 
was identical to DAPK-115. Further investigation is needed to elucidate the role of 
DAPK-1. In this study, DAPK-1 only refers to the form without the 12aa extension.    
 
1.4 Kinase activity of DAPK-1 
Calcium calmodulin Kinases (CaMKs) are activated by a release-of-autoinhibition 
mechanism19, 20. The regulatory domains of CaMKs contain an autoinhibitory region 
and a CaM recognition region (Figure 1.3). Binding of activated CaM to the CaM 
recognition region induces a conformational change that releases the steric block of 
the active site by the autoinhibitory region. It is also common that the activity of 
CaMKs is regulated by phosphorylation on the CaM regulatory domains and the 
effects of the phosphorylations vary. For example, CaMKII contains an 
autophosphorylation site on its autoinhibitory region that allows a prolonging of the 
CaM activation20. Myosin light chain kinase (MLCK) contains a phosphorylation site 
on its CaM recognition region that decreases its affinity with CaM20. 
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Like other CaMKs, the catalytic activity of DAPK-1 is greatly enhanced when Ca2+-
activated CaM binds to its CaM regulatory domain8. A deletion mutant of DAPK-1 
lacking the CaM binding domain displays a constitutively active kinase activity and 
induces phosphorylation independent of CaM binding in vitro8, confirming the effect 
of the autoinhibitory region on the CaM regulatory domain. In addition, a single-
point mutation of Ser308 on the CaM recognition region into alanine, which mimics 
the dephosphorylated form of DAPK-1, displayed a significant elevation in CaM 
binding and kinase activity in vitro; while another mutation of Ser308 to aspartic acid 
that mimicked the phosphorylated form of DAPK-1 strongly reduced the binding to 
CaM and minimized the DAPK-1 kinase activity21. These data suggest that 
phosphorylation on Ser308 of DAPK-1 has an inhibitory effect towards its kinase 
activity. Moreover, a kinase dead mutant of DAPK-1 (K42A) lost the Ser308 
phosphorylation21, indicating that the kinase activity of DAPK-1 is regulated by an 
autoinhibitory mechanism via autophosphorylation of Ser308 on the CaM 
recognition region21. Phosphorylation on Ser308 is Ca2+/CaM independent and is 
inhibited by the addition of Ca2+/CaM21. This suggests that the autophosphorylation 
on Ser308 favours the conformation required for binding to the autoinhibitory region, 
thus creating a two-step mechanism for activation of DAPK-1. In summary, in order 
to fully activate DAPK-1 in cells, the dephosphorylation of Ser308 and the addition 
of Ca2+/CaM are both required.  
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1.5 Localization of DAPK-1 
The intracellular localization of DAPK-1 is an important aspect for understanding its 
function. It was published in 1997 that DAPK-1 localized to the cytoskeleton via its 
cytoskeletal binding domain8. It was subsequently discovered that DAPK-1 localized 
to actin stress fibers of the cytoskeleton and that this localization requires its ankyrin 
repeats region in addition to the cytoskeletal binding domain22, 23. It has been shown 
that proteins containing ankyrin repeats are able to prevent microtubule-dependent 
vesicular transport24, suggesting a possible interaction between ankyrin repeats and 
microtubules. Indeed, a recent study demonstrated that DAPK-1 can interact with 
tubulin and colocalize with mibrotubules25. However, it has to be noted that although 
DAPK-1 demonstrates a strong colocalization with the cytoskeleton, a diffused 
DAPK-1 staining in the cytoplasm is also observed in all the published works 
together with the cytoskeletal co-staining22, 23, 25. This suggests that in vivo there may 
be several pools of DAPK-1, which differ from each other in their binding partners 
and localization.  
 
1.6 Expression of DAPK-1  
1.6.1 Tissue specific expression of DAPK-1 
Tissue distribution and developmental changes in mRNA expression can in part 
reflect the physiological role of a gene. Several groups investigated the mRNA 
expression of DAPK-1 by Northern blot and in situ hybridization analyses, and found 
that DAPK-1 was expressed predominantly in brain and lung, and with relatively 
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high levels in heart, spleen, eye ball and kidney26, 27. In brain, DAPK-1 mRNA 
appeared at embryonic day 13 and was detected thereafter throughout the embryonic 
period. At postnatal stage, the expression of DAPK-1 is restricted to the 
hippocampus26, 27. These data suggest that DAPK-1 mRNA is under strict regulation 
during development. Although it has been reported that DAPK-1 null mice have no 
significant developmental defects15, mutation of a negative regulator of DAPK-1 
activity could lead to overactive DAPK-1 during development and cause defects or 
lethality.  
 
1.6.2 DNA methylation of DAPK-1 gene 
DNA methylation is an enzyme-mediated chemical modification that adds methyl 
(CH3) groups at selected sites on DNA (Figure 1.4)
28. In humans, DNA methylation 
is the only known natural modification of DNA, and only affects the Cytosine base 
(C) when it is followed by a Guanosine (G)28. Thus the DNA methylation sites on 
human genes are called CpG islands. Gene silencing by DNA methylation is a well-
known mechanism in tumourigenesis and promoter methylation mediated expression 
loss of a number of tumour suppressor genes like p16 or Rb has been demonstrated 
in various cancers28. 
 
In 1997, a survey of DAPK-1 mRNA and protein expression in cell lines derived 
from human B cell neoplasms, bladder, breast and renal cell carcinomas discovered 
loss of DAPK-1 expression in these cell lines and this loss was not due to a deletion 
or rearrangement of the DAPK-1 gene, but due to the epigenetic silencing of the gene 
by DNA methylation29. The follow-on work by the same group in 2001 revealed that 
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the DAPK-1 gene was methylated in 26% of the primary tumour samples from 
patients with colon cancer30. From then on, a massive amount of research by 
different laboratories investigated DAPK-1 gene methylation and expression in 
various human tumours. In many cases, the detection of methylation in a certain 
region of DAPK-1 gene by methylation specific PCR correlated well with the loss of 
DAPK-1 mRNA expression. Today, DNA methylation-mediated DAPK-1 
expression loss has been observed in various cancers originating from different 
tissues, including lymhomas and leukemias, lung, breast, colon, cervix, prostate and 
brain31-42. Therefore, loss of DAPK-1 expression by DNA methylation in cancers 
seems to be a general phenomenon and strongly suggests a tumour suppressor role of 
DAPK-1. The strongest support for this assumption came from a recent study 
showing that loss or reduced expression of DAPK-1 underlies cases of heritable 
predisposition to chronic lymphocytic leukaemia (CLL) and the majority of sporadic 
CLL, in which epigenetic silencing of DAPK-1 by DNA methylation on its promoter 
region occurs in almost all cases43.  
 
In some cases, however, DAPK-1 gene methylation status does not correlate with its 
expression. For example, it has been reported that for some B cell and lung cancer 
cell lines, treatment of the DNA methylation inhibitor 5’-azadeoxycytidine (5-aza-dC) 
did not restore the expression of DAPK-129, 44. Loss of DAPK-1 expression in the 
absence of DNA methylation has also been observed45-47. The mechanisms 
underlying this DNA methylation independent expression loss of DAPK-1 is still 
unclear. One study demonstrated that loss of heterozygosity was responsible for loss 
of DAPK-1 expression in around 15% of human colon and breast cancer samples30. 
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Another two studies showed that homozygous deletion of DAPK-1 gene in pituitary 
tumours and soft tissue leiomyosarcomas led to loss of DAPK-1 expression48, 49. 
These studies showed the complexity in tumour genesis and provided more clues in 
understanding the role of DAPK-1 in cancer at genetic level.  
 
1.6.3 General degradation pathway 
In addition to transcriptional regulation, the expression of intracellular proteins are 
also regulated by post-translational degradation pathways at rates spanning from a 
few minutes to many days. For example, the protein half life of ornithine 
decarboxylase (ODC) is around 10 minutes, while that of glucose-6-phosphate 
dehydrogenase (G6PD) is 15 hours50. Two major pathways for protein degradation 
have been identified in eukaryotic cells, i.e. the lysosomal pathway and the ubiquitin-
proteasome pathway.  
 
Lysosomes are organelles containing acidic hydrolases that predominantly degrade 
long-lived protein and organelles. Lysosomal degradation is utilised in digestion 
processes such as pinocytosis and phagocytosis, which ingest other dying cells or 
exogenous proteins and particles, endocytosis to recycle the membrane bound 
receptor proteins, and   microautophagy and macroautophagy to digest unneeded 
proteins and organelles to produce energy (Figure 1.5)50. Proteases of the cathepsin 
family are the best studied lysosomal hydrolases51. The term “cathepsin” stands for 
“lysosomal proteolytic enzyme” regardless of the enzyme class52. Therefore, 
cathepsins can be divided into three subgroups according to their active-site amino 
acid, i.e. cysteine, aspartate and serine cathepsins53. They are synthesized as inactive 
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preproenzymes, post-translationally glycosylated and directed to the lysosomal 
compartment by cellular mannose-6-phosphate receptors52. Cathepsins are optimally 
active in the acidic pH of lysosome (pH4-5), but can also function in more neutral 
pH outside of the lysosome but with lower efficacies51.  
 
The 26S proteasome in eukaryotic cells is a barrel-shaped multiprotein complex that 
predominantly degrades short-lived proteins54. It is composed of two sub-complexes, 
a 20S subunit containing the catalytic activity and a 19S regulatory subunit55. 
Degradation of a protein via the ubiquitin-proteasome pathway involves two 
successive steps; conjugation of ubiquitin,  followed by degradation of the ubiquitin 
tagged protein by the downstream 26S proteasome complex50. Ubiquitin is an 
evolutionarily conserved 76-residue globular protein present in all eukaryotes and is 
usually attached to lysine side chains of target proteins, resulting in branched and 
isopeptide-linked ubiquitin-protein conjugates (ubiquitination)56. Ubiquitination is a 
very complicated process and can act as a signal for protein to be targeted for 
proteasomal degradation. The conjugation of ubiquitin with the substrate proceeds 
through a three-step cascade mechanism (Figure 1.6). Three classes of enzymes 
known as E1, E2 and E3 are involved in this process. Initially E1 activates ubiquitin 
for conjugation by using the energy of ATP to form a high-energy thiolester linkage 
with the C-terminus of ubiquitin. Then, one of several E2 enzymes, which also bind 
ubiquitin covalently through a thiolester bond, transfers the activated ubiquitin 
moiety to the substrate protein either directly or via an E3 ligase56. In many cases, 
E3s play a key role in ubiquitination since they mediate the highly specific 
recognition of the target proteins that are to be degraded. However, the mechanisms 
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through which E3s select substrates remains the poorest understood part of the 
ubiquitination process. To date, the known E3s can be classified into two major 
families: the HECT (Homologous to E6-AP C-Terminus) domain containing E3s and 
the structurally related RING-Finger/U-box  domain containing E3s56.The HECT 
domain can directly bind to ubiquitin via a thioester bond and then transfer ubiquitin 
to the substrate, while the RING/U-box domain usually acts as a docking station for 
the substrate and the E2 enzyme57. The RING domain is stabilized by Zn2+ ions 
mediated by the cystine and a histidine on it, whereas the U-box is stabilized by a 
system of salt-bridges and hydrogen bonds58. Interestingly, all mammalian U-box 
containing proteins have been reported to interact with molecular chaperones or co-
chaperones, suggesting an important role of these proteins in mediating the 
degradation of unfolded or misfolded proteins59.   
 
Although the best-studied function of ubiquitination is targeting substrates towards 
proteasomal degradation, there are other functions for ubiquitination and there exist 
several distinct types of ubiquitination. Substrates can be monoubiquitinated or 
polyubiquitinated, and polyubiquitin chains can be linked through any of the seven 
lysine residues in ubiquitin60. In cells, monoubiquitination primarily regulates 
subcellular relocalization of substrates61. In humans cells, polyubiquitin chains are 
usually linked by Lys-48 or Lys-63 residues61.  Lys-48-linked ubiquitin chains often 
target substrates for proteasomal degradation and in order to accomplish this function 
must contain at least four ubiquitins61. Lys-63-linked ubiquitin chains generally don’t 
promote degradation, but are involved in regulating protein activity and localization61.  
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1.6.4 Degradation of DAPK-1 
Not much is known about the degradation mechanisms regulating DAPK-1. It was 
reported that DAPK-1 can be degraded via the ubiquitin-proteasome pathway and 
two ubiquitin E3s have been identified that target DAPK-1 towards the proteasome. 
The first is DIP-1 (MIB-1), which was a RING domain E3 and reported to interact 
with the ankyrin repeats region on DAPK-1 and is able to actively ubiquitinate and 
degrade DAPK-162. The other is the carboxyl terminus of HSC70-interacting protein 
(CHIP), which is a U-box-containing E3 ubiquitin ligase that can bind to Hsp90 and 
Hsp7063. CHIP facilitates the ubiquitination of some Hsp90 client proteins63 and as a 
Hsp90 interacting protein, DAPK-1 is targeted for degradation by CHIP64.  
 
Little is known about lysosomal degradation of DAPK-1. however it was 
demonstrated that DAPK-1 is associated with the cysteine protease cathepsin B in 
the lysosome65, 66. Previous reports also demonstrated that DAPK-1 can be cleaved to 
yield a 60KDa product65, 66 and that the accumulation of the 60KDa cleavage product 
of DAPK-1 protein is specifically blocked by a cathepsin B inhibitor66, suggesting 
that DAPK-1 can be cleaved by cathepsin B. Moreover, the observation that DAPK-
1 is involved in regulating autophagy strongly suggests that DAPK-1 can be 
regulated via an alternative lysosomal degradation pathway.  
 
1.7 Interactive partners of DAPK-1  
Protein-protein interaction refers to the association of protein molecules and forms 
the basis of signalling pathways and foundation of all biological activities in cells. As 
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DAPK-1 is reported to be involved in multiple signalling pathways, it is important to 
understand its interactive partners in order to comprehensively understand the 
molecular mechanisms underlying the biological functions of DAPK-1. This section 
will introduce all the known and predicted proteins that can directly interact with 
DAPK-1. The roles of these interactions in signalling pathways involving DAPK-1 
will be discussed together with the biological functions of DAPK-1 in section 1.7.  
 
1.7.1 Substrates of DAPK-1 
Being a Ca2+/CaM dependent serine/threonine kinase, the substrates of DAPK-1 are 
naturally the first interesting interactive partners to study. Due to lack of DAPK-1 
substrates at the early stage in the field, the search for a DAPK-1 phosphorylation 
consensus motif was carried out in 2001 using positional scanning substrate library 
synthesis and activity screens67. A peptide analogue of the myosin light chain (MLC) 
phosphorylation site was used as a starting point because MLC is the first identified 
substrate for DAPK-1 and not much was known about other substrates at that time67. 
The result showed that DAPK-1 has a preference for basic residues in the core P-2, 
P-1 and P1, although a variety of amino acids are tolerated at these positions. For 
example, peptides with D or N at P1 and R or K at P-2 are more effectively 
phosphorylated by DAPK-1. Moreover, DAPK-1 has a loose preference for positive 
charged amino acids R or K further upstream67. In conclusion, the consensus for the 
DAPK-1 phosphorylation site based on the study of MLC is KRxxxxxKRxxS/T 
(Table 1.1).  
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More recently, a new method using biochemical fractionation and mass 
spectrometric analysis to purify and identify potential substrates from HeLa cell 
lysate was developed68. Total Hela cell lysate was subjected to consecutive 
fractionation using phenyl-HP hydrophobic column and then incubated in vitro with 
a recombinant protein consisting of the catalytic domain of DAPK-1. The 
corresponding phosphorylated substrates were then cut out of the gels and sent for 
mass spectrometric analysis68. Minichromosome maintenance complex component 3 
(MCM3), which is a DNA replication licensing factor, was pulled out by this method 
and proved to be phosphorylated by DAPK-1 not only in vitro, but also in vivo at 
Ser16068. This success indicates the usefulness of this approach in identifying new 
physiological substrates of DAPK-1 and may greatly shorten the time spent on 
searching for new substrates of DAPK-1 in the future.   
 
The DAPK-1 substrates identified to date include CaM-regulated protein kinase 
kinase (CaMKK), DAPK-1 itself, MCM3, MLC, cell cycle regulator p21, p53, 
ribosomal protein S6, neural protein Syntaxin-1A, tropomyosin-1 and the DAPK-1 
family member ZIP kinase (Table 1.1). Not all these substrates match the identified 
consensus motif (Table 1.1). However, the consensus does provide a clue for 
predicting the potential substrates of DAPK-1 and will be helpful in identifying new 
substrates for DAPK-1.  
Table 1.1 Known substrates of DAPK-. The amino acids and numbers in red signify the 
phosphorylation site. Proteins are listed in alphabetical order.  











ZIP kinase74 KT299TRLKEYTIKS309HS311S312LPPNNS318YADFERFS326 
Consensus KRxxxxxKRxxS/T 
 
Although the sites of phosphorylation on these substrates by DAPK-1 have been 
defined, the functions of some phosphorylations are still not clear. For example, the 
effect of phosphorylation of p53, p21 and MCM3 have not been clearly demonstrated. 
Moreover, phosphorylation on Ser235 of ribosome protein S6 was suggested to 
inhibit its activity in vitro71. However, the same phosphorylation on Ser235/Ser236 
was reported by other groups to promote its activity75. This contradiction highlights 
the lack of understanding of the function of these phosphorylation events, thus more 
experiments are required to clarify the functional effects of the phosphorylations.   
 
1.7.2 Binding partners of DAPK-1 
All the DAPK-1 substrates are binding partners of DAPK-1. Moreover, as a protein 
containing multi-functional domains, DAPK-1 has other binding partners in addition 
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to its substrates that can interact with its other functional domains. So far, the known 
non-substrate binding partners of DAPK-1 include 14-3-3, CaM, extracellular signal-
regulated kinase (ERK), Fas-associated protein with death domain (FADD), heat 
shock protein 90 (Hsp90), Leukocyte common antigen-related phosphatase (LAR), 
microtubule-associated protein 1B (MAP1B), mind bomb 1 (MIB1), protein kinase 
D (PKD), Tyrosine kinase Src, tumour necrosis factor receptor 1 (TNFR-1) and 
netrin-1 recepter UNC5H2 (Table 1.2).  
Table 1.2 Known binding partners of DAPK-1. The proteins are listed in the alphabetical order.  
Binding protein Binding region on DAPK-1 
14-3-376 Not yet identified 
CaM8 Ca2+/CaM regulatory domain 
ERK77 Death domain 
FADD76 Not yet identified 
Hsp9078 Kinase domain 
LAR79 Ankyrin repeat region 
MAP1B25 Kinase domain 
MIB162 Ankyrin repeat region 
PKD80 Not yet identified 
Src79 Not yet identified 
TNFR-176 Not yet identified 
UNC5H281 Death domain 
 
As shown on Table 1.2, the region on DAPK-1 important for binding to some 
partners has not been defined. For example, 14-3-3, TNFR-1 and FADD are shown 
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to interact with DAPK-1 in rat neuron cells after brain seizure76. Presumably, as 
death domain containing proteins, they should all be able to interact with DAPK-1 
via their death domains. However, no experiments have been performed to confirm 
this assumption. Moreover, the functional significance of these interactions is not 
clear.  
  
1.7.3 Predicted DAPK-1 interactive proteins 
In addition to all the known interactive partners, there are still many DAPK-1 
interactive proteins awaiting for discovery. For example, DAPK-1 can induce cell 
death through the p19ARF-p53 pathway or by inhibiting integrins and extracellular 
matrix (ECM) signalling15. However, DAPK-1 doesn’t seem to directly interact with 
p19ARF or integrins. Moreover, DAPK-1 was also reported to induce autophagy, 
while no interactions between DAPK-1 and any autophagy related genes have been 
found. Therefore, there must be some unknown proteins that link DAPK-1 and the 
reported downstream signalling pathways. It is a great challenge to find these 
unknown DAPK-1 interactive partners in order to further elucidate the functional 
role of DAPK-1.  
 
1.8 Cellular functions of DAPK-1  
1.8.1 Cell death pathways 
Although the term “apoptosis” is often used to describe cell death, there exist some 
other morphologically and biochemically different forms of cell death (Figure 
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1.7)82.Cell death falls into several categories and the difference between them are not 
very clear. In general, cell death can be divided as non-physiological (necrotic) cell 
death and physiological cell death, which consists of autophagic cell death and 
apoptosis (Figure 1.8)83. Therefore, it is very important to distinguish the unique 
characteristics of these cell death pathways and find out which type of cell death 
DAPK-1 participates in.  
 
As the most typical PCD, apoptosis is characterized by morphological changes such 
as cell shrinkage and rounding, cytoplasm condensation, chromatin condensation and 
fragmentation, packaging of the decreased cell into apoptotic bodies without plasma 
membrane breakdown and finally removal of apoptotic bodies by phagocytes like 
macrophages (Figure 1.7c)3, 82, 84, 85. These morphological features of apoptosis can 
occur dependent or independent of the cysteine protease caspase cascade, which 
plays an essential role in the execution of apoptosis83. Caspases are activated by 
either death receptor ligation (Extrinsic pathway)86 or disruption of mitochondrial 
membrane potential (m) (Intrinsic pathway)87 (Figure 1.8,1.9), and requires energy 
in the form of ATP83. In the intrinsic pathway, when its potential is disrupted, 
mitochondria release into the cytosol a small protein cytochrome c, which first binds 
with Apaf-1 (apoptosis protease activating factor 1) and ATP, and then binds to pro-
caspase 9 to create a protein complex known as an apoptosome. The apoptosome 
cleaves pro-caspase 9 to its active form of caspase-9, which in turn activates caspase 
3 and caspase 7 that execute apoptosis (Figure1.9)61. In the extrinsic pathway, the 
execution of apoptosis also requires caspase 3 and caspase 7 (Figure 1.9). 
Importantly, there is a great deal of crosstalk between the intrinsic and extrinsic cell 
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death pathways (Figure 1.9). For example, in response to stress, mitochondria also 
release proteins called Smacs (second mitochondria-derived activator of caspases), 
which binds to the IAPs (inhibitor of apoptosis proteins) such as XIAP (X-linked 
IAP), cIAP1 (cellular IAP 1) and cIAP2 to relieve their inhibition of caspase 9, 
caspase 3 or caspase 7, thus promoting apoptosis (Figure 1.9)88, 89.  
 
A large amount of proteins are involved in the regulation these distinct apoptotic 
pathways61. Of note, some death receptor pathways possess both pro- and anti-
apoptotic functions in the extrinsic pathway. For example, TNF- can activate both 
survival and apoptosis pathways (Figure 1.9)61. There are two TNF- receptors, 
TNFR-1 and TNFR-290. TNFR-1 is found in most cells and activated by soluble 
ligand90. TNFR-2 is primarily expressed in haemopoietic cells and mainly activated 
by membrane-integrated ligand90. Studies using TNFR-1 and TNFR-2 deficient mice 
suggest that TNFR-1 mediates most of the apoptosis, proliferation and pro-
inflammatory pathways downstream of TNF-, while the TNFR-2 mediated 
signalling is less well characterized91. In TNFR-1 signalling, the default effect is 
induction of genes involved in inflammation and cell survival92. When TNFR-1 is 
ligated to TNF-, it starts to bind to TRADD, which recruits the secondary adaptors, 
RIP-1, TRAF2 or TRAF5, forming receptor complex I (Figure 1.9)61, 92. Receptor 
complex I catalyzes the phosphorylation and degradation of the NF-B inhibitor, I-
B, which results in the translocation of transcription factor NF-kB (composed of 
two subunits RelA and p50 ) into the nucleus where it can induce the expression of 
pro-inflammatory genes as well as a series of negative regulators of apoptosis such as 
cFLIP (Cellular caspase-8 (FLICE)-like inhibitory protein) and Bcl-2 (B-cell 
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CLL/Lymphoma 2)93. If the NF-B signal is not successful, complex I can then 
disassociate from the membrane bound TNFR-1 and bind to the protein FADD in the 
cytosol, which mediates the recruitment of caspase 8 and caspase 10 to induce 
apoptosis through caspase 3 and caspase 7 (Figure 1.9)93.  
 
There are reagents that can switch TNF- from inflammation and survival to its 
apoptotic function. For example, the protein synthesis inhibitor cycloheximide (CHX) 
can promote TNF- induced apoptosis. It has been suggested that  CHX facilitates 
TNF- mediated apoptosis by suppressing the synthesis of the anti-apoptotic, NF-KB-
regulated bcl-2 and cFLIP proteins94-96, In addition, co-treatment with the pro-
apoptotic protein Smac or a Smac peptide mimetic has also been found to sensitize 
human cancer cells to TNF- induced apoptosis, probably due to Smac’s ability to 
block the inhibitor of apoptosis proteins (IAPs)89, 97. The lysosomal protease 
cathepsin B can participate in TNF- induced apoptosis in some cellular contexts. 
For example, it has been reported that isolated cells from cathepisn B-knocked-out 
mice are resistant to TNF- induced apoptosis and the cathepsin B null mice were 
protected from TNF- induced liver damage98, suggesting an important role of 
cahtepsin B in the TNF- stimulated apoptosis pathway in liver cells. However, 
although this model is also consistent with some experiments performed in human 
cells99, the opposite results have been observed, showing cathepsin B in not involved 
in TNF- induced apoptosis100. Therefore, the exact role of cathepsin B in TNF- 
pathway may vary according to the cellular conditions.  
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Autophagy is a cellular catabolic response to a lack of nutrients or to stress. During 
autophagy, cellular proteins, organelles and bulk cytoplasm are sequestered into 
double-membrane vesicles called autophagosomes. Autophagosomes then fuse with 
lysosomes to form autophagolysosomes where the sequestered cargo is degraded and 
recycled to provide energy for the cells101. The morphological characteristics of 
autophagy are the formation of double-membraned autophagosomes, nuclear 
condensation without DNA fragmentation and an intact and functional cytoskeleton 
until late in the process (Figure 1.7b)102. As shown in section 1.6.3, autophagy is 
intimately linked to the  lysosomal degradation pathway (Figure 1.5).  
 
The core molecular machinery of autophagy is highly conserved in yeast, C.elegans, 
Drosphila and mammals103. , In the mammalian system  31 autophagy-related genes 
(ATGs) have been identified104. The core machinery of autophagy is based on two 
systems similar to the ubiquitin cascade, which deliver small ubiquitin-like proteins 
to its binding partners with the help of some E1 and E2-like proteins (Figure 1.10). In 
one system, Atg12 was first activated by Atg7, and then transferred to Atg5 by 
Atg10, to form a complex. The Atg5-Atg12 complex then interacts with tetramer 
Atg16 to form a multimer complex that localizes to membranes of early 
autophagosomes105, 106. The assembly of this system is independent of autophagy 
activation and therefore may provide a platform for autophagy activation. In the 
other system, Atg8, the mammalian ortholog of which is microtubule-associated 
protein 1 light chain 3 (LC3), is first cleaved by Atg4 to expose its C-terminal 
conserved Gly120. Atg8/LC3 is then transferred to phosphatidylethanolamine (PE) by 
Atg7 and Atg3107. Unbound Atg8/LC3 (named LC3-I) is in the cytosol, whilst the 
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conjugated form (named LC3-II) is localized to the autophagosomal membrane by 
the Atg5-Atg12-Atg16 complex107. The association of Atg8/LC3-PE complex to the 
autophagosome is important for the autophagosome membrane extension and the 
closure of the membrane to form vesicles. When the autophagosomes are mature, the 
Atg12-Atg5 complex detaches from autophagosomes, whereas Atg8/LC3 stays 
trapped on the membrane until it is degraded by the lysosomes. Therefore, Atg8/LC3 
is widely used as a marker for autophagy106.  
 
Although autophagy was initially discovered as a process that allows cells to survive 
times of famine, it is also found to participate in cell death. For example, loss or 
reduction of autophagy regulating proteins such as Atg7 and Beclin-1 attenuate 
apoptosis-independent cell death108-111, suggesting a positive role for autophagy in 
cell death. The dual roles of autophagy in cell death and cell survival are intriguing, 
but make it difficult to understand how autophagy chooses between survival and 
death. Some genetic studies may provide some clues. In C.elegans, in response to 
starvation, excessive or insufficient  autophagy both lead to cell death, suggesting 
that only a balanced level of autophagy is cytoprotective112. Moreover, although the 
beclin-1 knock-out mice died early in embryogenesis, beclin-1 heterozygous  mice 
displayed high incidence of spontaneous tumours, suggesting overactive survival 
pathways in these single allele knock-out mice113. Taken together, it seems the level 
of autophagy is very important for determining the cell fate. However, the 
physiological level of autophagy may vary among cell lines, tissues and species. 
There is no morphological or biochemical difference between autophagic cell 
survival and autophagic cell death since autophagosomes are the main characteristics 
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of autophagy. In addition, autophagy was found to collaborate with or even induce 
apoptosis and necrosis114-119, suggesting intense cross-talk between autophagy and 
other cell death pathways. Therefore, so far there is still little known about the actual 
“physiological” level of autophagy in cells and makes it difficult to interpret the 
function of autophagy when autophagic morphology is observed in cells. It is 
possible that autophagy is a “checkpoint” process for cells. Different from cell cycle 
checkpoint, autophagy is not stimulated by DNA damage, but by nutrient or energy 
insufficiency. Its primary function is to provide energy and nutrient to help cells 
survive famine. But when cells are exposed to cell death signals or the environmental 
conditions are too harsh, autophagy can in turn participate in and facilitate cell death 
processes like apoptosis and necrosis. Of note, it doesn’t mean that autophagy is an 
indispensable step before cell death, since cell death can be stimulated independently 
of autophagy82. The exact biochemical mechanisms underlying the cross-talk 
between autophagy and other cell death pathways are still unclear and require a lot of 
work in the future. Ideally, some specific markers for autophagic cell survival or 
death such as poly (ADP-ribose) polymerase (PARP) cleavage for apoptosis will be 
discovered, and thus will greatly help identify the actual role of autophagy under 
different conditions.  
 
In contrast to the physiological cell death processes, necrosis is a result of energetic 
catastrophe such as ATP depletion and has been characterized morphologically by 
vacuolation of the cytoplasm, breakdown of the plasma membrane and an induction 
of inflammation around the necrotic cells (Figure 1.7d)82, 120. Because necrosis leads 
to disintegration of cells, not much is known about the biochemical alterations of this 
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process and the only way to measure necrosis so far is to monitor morphological 
changes. Therefore, in some assays like Trypan blue staining, it’s very difficult to 
distinguish apoptosis and necrosis, and the use of additional apoptosis markers are 
required to confirm the type of cell death being observed.  
 
1.8.2 Cell death and autophagy induction by DAPK-1 
In order to study the physiological role of DAPK-1, the most elegant and convincing 
tools may be knock-down of DAPK-1 expression by RNA interference or knock-out 
of DAPK-1 gene through gene targeting. Early experiments showing that DAPK-1 
antisense cDNA attenuated IFN- and Fas induced cell death7, 121 suggest that the 
primary function of DAPK-1 is to induce cell death. Later on, the DAPK-1 knock-
out mouse was created15. Although no defects were observed in developmental cell 
death in these DAPK-1 -/- mice, some experiments with the primary cells derived 
from the knock-out mouse further suggest a death-promoting role of DAPK-1. For 
example, DAPK-1 -/- hippocampal neurons were more resistant to ceramide-induced 
cell death than their wild type counterparts122. DAPK-1 -/- mouse embryonic 
fibroblasts (MEFs) displayed decreased levels of apoptosis in response to forced 
expression of oncogenes c-myc and E2F compared to wild-type MEFs123. UNC5H2-
mediated cell death was also partially attenuated in DAPK-1 -/- MEFs81. In addition, 
retinal ganglion cells obtained from DAPK-1 -/- mice displayed increased survival 
compared to control (79% vs 56%) following administration of glutamate124. All 
these data support the notion that DAPK-1 is a physiological death-promoting kinase.  
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Ectopic expression of DAPK-1 or its mutants can in another way provide a clue to its 
cellular functions. The mutants in theory should antagonize the function of 
endogenous DAPK-1, although the high level of ectopically expressed DAPK-1 
usually bypasses the physiological level of DAPK-1. Ectopic overexpression of wild 
type DAPK-1 was shown to be sufficient to induce cell death in various cell lines8, 77, 
121, 123, 125-127. It was also found to enhance cell death induced by ceramide128, 
UNC5H281 and MEK (mitogen-activated protein kinase)/ERK77 signalling. The 
kinase dead mutant of DAPK-1 (K42A) and some miniprotein of interfering 
fragments, such as the death domain, have also been widely used. They have been 
found to antagonize multiple cell death signals like Fas121, ceramide122, 128, TGF-126 
and so on. However, although being enlightening, the data obtained from the mutant 
overexpression, especially fragment overexpression, may not necessarily reflect the 
role of DAPK-1. For example, DAPK-1 is a cytoplasmic protein, which is 
determined by its cytoskeletal binding domain and ankyrin repeats region as 
mentioned in section 1.4. The death domain miniprotein or the kinase domain 
miniprotein may move into the nucleus and, interfere with some signalling pathways 
that full-length DAPK-1 would never do. Extra caution is needed when interpreting 
data on these fragment mutants.  
 
DAPK-1 was found to actively participate in apoptosis pathway. In addition to IFN-, 
DAPK-1 was shown to positively regulate apoptosis downstream of other stimuli 
including Fas ligand121, TGF-126, ceramide122, 128, TRAIL129, brain seizure and 
ischemia66, 76, 130, cell detachment from extra cellular matrix127 and forced expression 
of oncogenes like c-myc and E2F123. Moreover, DAPK-1’s binding partner ERK was 
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found to stimulate apoptosis through DAPK-1 when cells are exposed to active MEK 
signal77, 131. Besides, another DAPK-1 binding partner UNC5H2 was reported to 
induce apoptosis partially via DAPK-181. However, in the UNC5H2 paper, Trypan 
blue was the only assay for measuring cell death. Considering Trypan blue is more 
sensitive for necrotic cells, it may suggest that DAPK-1 can also be involved in 
necrosis.   Actually, one recent report demonstrated that when the cells were treated 
with H2O2, DAPK-1 can activate PKD and is required for the caspase-independent 
necrotic cell death induced by oxidative stress80, which further supports the idea that 
DAPK-1 can be involved in necrosis.  
 
Interestingly, DAPK-1 is not exclusively a positive regulator of cell death. Since its 
discovery, a lot of work has been carried out to investigate the role of DAPK-1 in the 
TNF- signalling pathway. It has been shown by several groups independently that 
DAPK-1 was neutral7, 126 or protective18 in TNF- induced apoptosis by comparing 
the response to TNF- treatment in DAPK-1 knocked-down and wild type cells. One 
opposing report demonstrated that overexpression of the death domain fragment of 
DAPK-1 can block TNF- induced apoptosis121, suggesting that DAPK-1 is a 
positive regulator of cell death in TNF- pathway. However DAPK-1 is able to bind 
to downstream factors in the TNF- pathway such as TNFR-1 and FADD 
presumably through death domain homotypic interaction76, therefore it is likely that 
the death domain miniprotein does not mimic the function of full-length DAPK-1 in 
vivo, and may interfere with the downstream functions of TNF- via non-specific 
bindings. Some more recent studies further proved that DAPK-1 is not a positive 
regulator in TNF- induced apoptosis; instead, it is a negative regulator. It was found 
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that in Hela cells, the expression of MIB1, an ubiquitin E3 ligase that degrades 
DAPK-1, promotes TNF--induced apoptosis62. In addition, although antisense 
depletion of DAPK-1 in Hela cells protects cells from IFN- induced apoptosis, it 
promotes TNF- induced apoptosis18. Therefore, although it functions as a death-
promoting kinase, DAPK-1 can also act as a survival factor under certain 
circumstances. 
 
It has been reported that DAPK-1 is involved in the regulation of starvation induced 
autophagy in C.Elegans112. In mammalian cells, DAPK-1 was reported to be 
necessary for interferon--induced autophagy125, albeit it does not seem to be crucial 
for starvation or rapamycin-induced autophagy31. Moreover, ectopic expression of 
DAPK-1 in some cell types can induce autophagy, as defined by the formation of 
autophagy markers such as autophagasomes25, 74, 125. These data suggest that there 
may be multiple signalling pathways that regulate autophagy pathways in cells and 
that DAPK-1 is only involved in some of them.  
 
Taken together, it is clear that DAPK-1 is involved in multiple cell death pathways. 
However, it has to be noted that most of the experiments showing DAPK-1 as a 
positive effector of apoptotic cell death were performed in the presence of other 
upstream signals such as IFN- or MEK/ERK. When DAPK-1 level was increased 
by ectopic transfection, the response observed in most reports is autophagy. The only 
experiment showing DAPK-1 overexpression per se induces apoptosis was 
performed in suspended cells, and thus the apoptosis induced was anoikis. As 
discussed above, autophagy may act as a checkpoint process. Therefore, it is possible 
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that the main function of DAPK-1 is to act as an autophagy regulator and its role in 
other cell death pathways vary according to cellular stimuli and environment. This 
indicates that DAPK-1 can have dual functions in cell fate, i.e. both survival and 
death, and may help to explain the controversial observation that DAPK-1 acts as a 
resistance factor in the TNF- death-signalling pathway. It is still unclear exactly 
how DAPK-1 contributes to apoptosis or necrosis, however with the increasing 
understanding of the complicated crosstalk between autophagy, apoptosis and 
necrosis, extra caution is needed when interpreting the roles of DAPK-1 in these 
pathways. 
 
The mechanisms through which DAPK-1 induces autophagy and cell death are still 
not clear, but the interactive proteins of DAPK-1 may provide some clues. For 
example, CaMKK is an enzyme key to maintain neuronal survival and 
phosphorylation by DAPK-1 attenuated its activity69. Phosphorylation of PKD by 
DAPK-1 enhances its activity to promote oxidative stress induced cell death80. 
Syntaxin-1A is a positive regulator of autophagy and its phosphorylation by DAPK-1 
enhanced its interaction with MUNC-18 (mammalian homologue of the unc-18 gene) 
and presumably increases its role to promote autophagy72. Moreover, DAPK-1 
induces apoptosis through p19ARF-p53 pathways. Although no direct interaction 
between DAPK-1 and p19ARF was observed, the discovery that DAPK-1 can 
phosphorylate p53 may provide a new angle for investigation132. Besides, interaction 
between ERK and DAPK-1 not only leads to phosphorylation of DAPK-1 by ERK 
that results in activation of DAPK-1 kinase activity, but also retain ERK in the 
cytoplasm that prevents its cytoprotective effect. These downstream pathways of 
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DAPK-1 display the complexity of this protein and clearly indicate that although the 
cellular outcome observed may be similar, DAPK-1 can achieve these outcomes via 
multiple cellular pathways in different cell types or under different stimuli. The 
identified interactive partners of DAPK-1 that are involved in apoptosis and 
autophagy are summarized in Table 1.3.   
Table 1.3 Known binding partners of DAPK-1that are involved in apoptosis and autophagy.   
Interactive protein Roles of the interaction in apoptosis and autophagy 
CaM8 Promote apoptosis 
ERK77 Promote apoptosis 
LAR79 Promote apoptosis 
MAP1B25 Promote autophagy 
PKD80 Promote cell death 
Src79 Inhibit apoptosis 
UNC5H281 Promote apoptosis 
ZIP kinase74 Prmote cell death 
 
1.8.3 Membrane blebbing induction 
In most eukaryotic cells, the plasma membrane is bound to the cell cortex, which is 
composed of actin, myosin and associated proteins133. Under certain circumstances, 
the plasma membrane separates from the cortex and expands into spherical 
protrusions called blebs (Figure 1.11) and membrane blebbing refers to the cell status 
when cells have blebs. Blebs differ from other cellular protrusions like lamellipodia 
or filopodia, because the growth of blebs is pressure-driven instead of being pushed 
against the membrane by polymerizing actin filaments134. In general, the life cycle of 
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membrane blebbing can be subdivided into three stages: bleb initiation, expansion 
and retraction (Figure 1.12)133. The bleb initiation can be caused by two distinct 
mechanisms, a local dissociation of the membrane from the cortex135 or a local 
rupture of the actin cortex136 (Figure 1.12a). After initiation, the hydrostatic pressure 
in the cytoplasm drives the cytosol fluid into the blebs, which leads to the size 
increase of the blebs (Figure 1.12b)133. The retraction step consists of reformation of 
cortex and the follow-on bleb retraction133. After the bleb expansion slows down, 
actin cortex repolymerization begins to form a new layer of cortex under the bleb 
membrane (Figure 1.12c)137. Then myosins are recruited to discrete spots on the new 
cortex and create a contractile force that mediates bleb retraction (Figure 1.12d)133.      
 
 
Membrane blebbing is primarily viewed as a morphological characteristic of 
apoptotic or necrotic cell. In addition, some studies demonstrated that membrane 
blebbing can be induced by the reassembly of the contractile cortex and act as part of 
a normal cell division process such as cytokinesis138. In addition, membrane blebbing 
has been observed in a lot of invasive cancer cells139. It has been shown that 
experimental induction of membrane blebbing in non-invasive cells promotes their 
ability to invade into 3D matrices139-141, suggesting that membrane blebbing enables 
cells to gain directed motility.  
 
In early studies, membrane blebbing was used as a marker to measure the apoptosis 
induced by DAPK-1 and overexpression of DAPK-1 significantly induced membrane 
blebbing in some cell types8, 74, 121. However, later studies suggested that membrane 
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blebbing induced by DAPK-1 may reflect autophagy instead of apoptosis25, 74, 125. It 
was shown that membrane blebbing induced by DAPK-1 was greatly enhanced when 
its binding partner MAP1B was cotransfected and could be inhibited by the treatment 
of autophagy inhibitor 3-methyladenine (3-MA)25, suggesting that DAPK-1 induces 
autophagy and that subsequently leads to membrane blebbing.  
 
Conversely, a recent study demonstrated that knockdown of endogenous DAPK-1 
attenuates oxidative stress induced membrane blebbing, suggesting at a physiological 
level a negative role of DAPK-1 in inducing membrane blebbing73. Tropomyosin-1 
is a protein reported to be phosphorylated downstream of the ERK pathway in 
endothelial cells activated by oxidative stress142, 143. The key role of tropomyosin-1 is 
to induce or stabilize actin stress fibres when it is phosphorylated at Ser283. DAPK-1 
was found to be the kinase that directly phosphorylates tropomyosin-1 at Ser283 
downstream of ERK73 upon oxidative stress. Interestingly, when DAPK-1 was 
knocked down, the cells lost stress fibres formation and underwent rapid membrane 
blebbing upon oxidative stress, which can be rescued by transfection of 
constitutively active tropomyosin-173. This report adds more complexity in 
understanding DAPK-1’s role in membrane blebbing.  
 
Membrane blebbing is initiated by increased myosin contractility, which has been 
reported to be induced by phosphorylation of MLC at Thr18 and Ser19, in 
conjunction with weakening of the structural integrity of the cortical actin network 
owing to proteolysis of many of its components15, 144-146. DAPK-1 was found to 
phosphorylate MLC at Thr18 and Ser19 directly22, 23 or indirectly through ZIP 
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kinase74. ZIP kinase localizes to both the nucleus and the cytoplasm and fractionates 
as momeric and trimeric forms74 and can phosphorylate MLC efficiently at both 
Thr18 and Ser19 in the cytoplasm. DAPK-1 phosphorylates ZIP kinase at six specific 
sites on its C-terminus, and these phosphorylations retain ZIP kinase in the 
cytoplasm as a trimer. Thus DAPK-1 greatly enhances MLC phosphorylation by ZIP 
kinase74.  
 
Moreover, phosphorylation of MLC was reported to be sufficient and necessary for 
the formation of stress fibres and focal adhesions147. However, the phosphorylation 
of MLC by DAPK-1 leads to formation of actin stress fibres, but not the concomitant 
stimulation of focal adhesion assembly22. Actually, in cells cultured in serum-
containing medium, DAPK-1 is even capable of inducing focal adhesion disassembly 
without affecting stress fibres22. This uncoordinated regulation of stress fibres and 
focal adhesions may disrupt the balance in the cytoskeletal structure and explains 
how enforced expression of DAPK-1 results in membrane blebbing.  
 
Of note, under oxidative stress, the MLC kinase inhibitor ML-7 was reported to 
cause rapid membrane blebbing similar to the effect when DAPK-1 was knocked- 
down with siRNA143. In addition to inhibition of MLC phosphorylation, ML-7 
treatment also led to decrease in tropomyosin-1 phosphorylation143 similar to the 
effect of DAPK-1 siRNA treatment, even though DAPK-1 is the kinase that is 
reported to directly phosphorylate tropomyosin-173. It has been reported that DAPK-
1 is insensitive to ML-722, which ruled out the possibility that ML-7 took effect via 
DAPK-1. Therefore, although the exact mechanisms are still unclear, ML-7 and 
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DAPK-1 siRNA both inhibit the phosphorylations of MLC and tropomyosin-1. 
Because both MLC and tropomyosin-1 are critical for stress fibre formation, this dual 
inhibition of both kinases may lead to focal adhesion misassembly and thus result in 
rapid membrane blebbing in cells under oxidative stress.  
 
The disruption of the homeostasis of the endogenous cytoskeletal structure in cells 
underlies the basic mechanism for membrane blebbing. Although the outcome may 
be the same, the cellular pathways leading to the outcome may vary dramatically. 
Therefore, when oxidative stress was applied, the activated pathways that lead to 
membrane blebbing are probably very different from those in DAPK-1 
overexpressed cells. For example, as mentioned previously, DAPK-1 can induce 
necrotic cell death by activating PKD under oxidative stress80. The interaction 
between PKD and DAPK-1 was greatly enhanced when H2O2 was applied
80. 
Therefore, although the basic function of DAPK-1 may be promotion of stress fibre 
formation, the actual role of this protein in membrane blebbing depends on the 
specific circumstances.  
 
Another important aspect about membrane blebbing induced by DAPK-1 is its 
relationship with autophagy. Although it was shown that 3-MA can inhibit the 
membrane blebbing induced by overexpression of DAPK-125, it has to be noted that 
3-MA is a general inhibitor of PI3 kinase (phosphatidyl-inositol 3-kinase), and thus 
interferes with numerous cellular processes besides autophagy148. Therefore, it can 
not be ruled out that 3-MA inhibited the membrane blebbing induced by DAPK-1 via 
pathways other than autophagy. Interestingly, it has been shown that treatment on the 
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highly metastatic human fibrosarcoma HT1080 cells with 3-MA can inhibit 
membrane ruffle formation independent of autophagy inhibition, as downregulation 
of Beclin-1, a protein required for autophagosome formation, did not have the same 
effect149. It is possible that autophagy and membrane blebbing observed in DAPK-1 
overexpressed cells are two independent pathways, or there is even the possibility 
that autophagy is actually the consequence of the membrane blebbing induced by 
DAPK-1, for the structural changes may cause stresses in cells that later lead to 
autophagy. So far the observation of concomitant membrane blebbing and autophagy 
is only observed in DAPK-1 overexpressed cells. More experiments are needed to 
clarify the relationship between autophagy and membrane blebbing and the role that 
DAPK-1 has in these processes.    
 
1.8.4 Inhibition of cell motility  
Cell migration is crucial for multiple biological processes, including embryonic 
development, wound healing, immune surveillance and metastasis of tumour cells. 
As mentioned above, membrane blebbing promoted cell motility in 3D matrices139-141. 
Therefore, in theory, the membrane blebbing caused by enforced expression of 
DAPK-1 should lead to enhanced cell motility. Conversely, it was found that 
overexpression of DAPK-1 actually inhibited random cell migration by reducing 
directional persistence and directed migration via blockage of cell polarization150. 
These effects are mediated by an inhibitory effect of DAPK-1 on talin head domain 
associated with integrin, thereby suppressing the integrin-Cdc42 polarity pathway150.  
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In addition to the specific integrin pathway inhibited by DAPK-1, there may be other 
reasons for the motility suppression effect observed. Of note, although DAPK-1 was 
shown to inhibit cell mobility, the number of cell protrusions was still markedly 
enhanced by DAPK-1 overexpression, suggesting the membrane blebbing promotion 
effect was the same in this assay150. Moreover, the cell migration rate after DAPK-1 
overexpression was not greatly reduced150 and the dramatic decrease in migration 
distance was actually caused by loss of directional persistence150. Interestingly, the 
cell movement assay in this report was performed only at 2D environment150, 
whereas most reports showing blebbing motility occurred in 3D matrices or living 
tissues133. Therefore, membrane blebbing caused by DAPK-1 might enable cells to 
migrate better in 3-dimensions, which was not able to be observed in the 2-D assay 
used and may instead cause a decrease in cell movement in a 2-D assay. Besides, 
wound healing migration was the major assay used to test DAPK-1’s function in this 
report150. Considering the multiple inflammation pathways activated in response to 
wounds and the complicated involvement of DAPK-1 in the cytokine signalling 
pathways, it is possible that some unknown signalling events were activated that 
synergize with DAPK-1 to inhibit random cell migration. To date, this is the only 
piece of work that connects DAPK-1 with cell motility. However, considering 
DAPK-1’s active role in membrane blebbing and as a tumour suppressor in multiple 
signalling pathways, this work may provide a new angle for investigating the actual 
function of DAPK-1.  
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1.9 Regulation of DAPK-1 
1.9.1 Regulation by dephosphorylation and phosphorylation  
The autoinhibition effect of the Ser308 phosphorylation provides a direct pathway 
for the activation of DAPK-1, i.e. dephosphorylation at Ser308 will lead to enhanced 
kinase activity of DAPK-1. Indeed many stresses activate DAPK-1 through 
dephosphorylation on this site, including TNF-151, ceramide151, cerebral ischemia66 
and mitochondrial toxins152.  
 
Interestingly, the phosphatase utilized by different pathways may vary. For example, 
it was shown that calcineurin (PP2B) was the phosphatase that dephosphorylates 
DAPK-1 at Ser308 during ischemia66. However, upon mitochondrial toxins treatment, 
calcineurin inhibitors could not rescue DAPK-1 from dephosphorylation, suggesting 
the existence of other phosphatases that can dephosphorylate DAPK-1 in this 
pathway152.  
 
In addition to Ser308, there are several other phosphorylation sites on DAPK-1 that 
can influence its catalytic activity (Figure 1.13). Interestingly, all these 
phosphorylation sites were related to growth factor-stimulated pathways. At first, it 
was found that ERK can directly interact with and phosphorylate DAPK-1 at Ser735, 
which led to enhanced kinase activity of DAPK-177. This Ser735 phosphorylation 
can be stimulated by serum or phorbol-12-myristate-13-acetate (PMA)77, which 
activates the Ras-MEK-ERK pathway153, 154. Subsequently, it was reported that 
RSK1/2 can directly interact with and phosphorylate DAPK-1 at Ser289 in response 
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to PMA155. The influence of this phosphorylation on the kinase activity of DAPK-1 
was not tested. However, mutation of Ser289 to alanine results in a DAPK-1 mutant 
with enhanced apoptotic activity, whereas the phosphomimetic mutation (Ser289Glu) 
attenuates its apoptotic activity155. To bring more complexity to the pathway, a recent 
report demonstrated that DAPK-1 can be phosphorylated by Src at Tyr491/492, and 
dephosphorylated by LAR at these two sites79. Phosphorylation of these sites has an 
inhibitory effect towards DAPK-1 kinase activity and is induced by EGF79.  
 
Because the Ser289Ala mutant of DAPK-1 is more apoptotic, it seems that this 
phosphorylation enhances the catalytic activity of DAPK-1155. However, considering 
the controversial roles of DAPK-1 in apoptosis, it is not necessarily the case. The 
increased apoptosis-promoting function may be caused by a decrease in the kinase 
activity of DAPK-1. Moreover, Ser289 locates at the autoinhibitory region of the 
CaM regulatory domain of DAPK-1 (Figure 1.3). Phosphorylations on this region 
tend to lead to activation of the CaMKs, rather than inactivation20. Therefore, kinase 
assays using the Ser289 mutants are needed to confirm the function of Ser289 
phosphorylation.  
 
The observation that serum, PMA and EGF all activate the growth factor pathways in 
cells creates extra difficulties in understanding the seemingly contradictory effects of 
DAPK-1 phosphorylations at Ser735 by ERK and that at Tyr491/492 by Src. Of note, 
in the Src/LAR paper, EGF was treated directly on cells growing in serum containing 
medium79. As mentioned in the previous papers of the same authors, the culture 
medium they used already contained a high concentration of EGF127 and DAPK-1 
 38
catalytic activity was increased following serum stimulation22. Therefore, the extra 
treatment of EGF in the Src/LAR paper may lead to an EGF concentration beyond 
the tolerance of the cells and super-active endogenous DAPK-1, which can be toxic 
to cells. Importantly, Src kinase was reported to activate Raf, which can activate the 
MEK/ERK pathway upstream of DAPK-1156. So it is possible that Src possesses dual 
functions. On one hand, it can activate DAPK-1 in response to growth factors via the 
MEK/ERK pathway; while on the other hand, it can directly phosphorylate and 
suppress DAPK-1 activity when growth factor signalling is over the limit tolerable 
by cells.  
 
1.9.2 Regulation of DAPK-1 transcription 
DAPK-1 gene expression was also found to be regulated in response to stress. For 
example, in neuronal cells, both seizures and ischemia were found to regulate 
DAPK-1 mRNA expression65, 66, 76. However, opposing effects were observed in 
neuron cells taken from different regions of the brain65, 66, 76 and the mechanisms 
which regulate DAPK-1 mRNA expression in response to stress was unclear.  
 
TGF- was reported to induce DAPK-1 expression126. TGF- significantly enhanced 
the level of DAPK-1 mRNA and the promoter activity of DAPK-1126. This induction 
is mediated by the Smad pathway and requires Smad2, Smad3 and Smad4126, 




Another transcription factor that is reported to regulate the transcription of DAPK-1 
through its promoter region is p53157. It was found that DNA damage stresses such as 
UV or Doxocycline induce DAPK-1 mRNA expression through p53, and the p53 
binding site on the DAPK-1 gene locates on intron 1157. c-Myc induced DAPK-1 
expression was also reported to be p53 dependent157, providing a mechanism for the 
previous observation that overexpression of oncogenes like c-Myc and E2F increase 
DAPK-1 expression123. Of note, in p53 -/- MEFs, the expression of DAPK-1 mRNA 
is not less than that in p53 +/+ MEFs, suggesting that p53 doesn’t control the steady 
state level of DAPK-1 expression157.  
 
A recent publication identified C/EBP- as a transcriptional regulator of DAPK-1 
that binds to the promoter region of DAPK-1 and is required for DAPK-1 steady 
state expression and its expression in response to IFN-158 Two elements on the 
promoter region of DAPK-1 were identified. One is a consensus C/EBP- site that 
permits constitutive binding of C/EBP-158. The other shows homology to the cyclic 
AMP response element/activating transcription factor binding sites. C/EBP- binds 
to this site in an IFN- dependent manner158. Interestingly, ERK mediated 
phosphorylation of C/EBP- at Thr189 is required for the interaction of C/EBP- 
with the IFN--dependent element on DAPK-1 promoter region, thus ERK is 
required for DAPK-1 induction by IFN-158. 
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1.9.3 Regulation of DAPK-1 degradation  
Not many stresses have been shown to induce the degradation of DAPK-1. The fact 
that CHIP targets DAPK-1 for degradation implies that Hsp90 acts to stabilize 
DAPK-1. It was shown that inhibition of Hsp90 by its inhibitors geldanamycin (GA) 
or 17-allyalamino-17demethoxy-geldanamycin (17-AAG) leads to degradation of 
DAPK-164, 78. This is consistent with previous findings that after Hsp90 inhibition, 
many of its client proteins are destabilized and subsequently degraded via the 
ubiquitin proteasome pathway159. Interestingly, knock-down of both MIB-1 and 
CHIP can attenuate this degradation64, suggesting that multiple ubiquitin-proteasome 
related factors can control DAPK-1 degradation after Hsp90 inhibition.  
 
The other stress that was clearly shown to degrade DAPK-1 was TNF-62, 64. 
Although MIB-1 was shown to promote TNF- induced apoptosis and degrade 
DAPK-1151, there was no direct evidence that TNF- degrades DAPK-1 via MIB-1. 
In addition, the effect of TNF- on the stability of DAPK-1 is much weaker than 
Hsp90 inhibitors and has to be used in combination with the protein translation 
inhibitor cycloheximide, suggesting that some other slower degradation pathways 
such as lysosomal pathway may be involved. In addition, ceramide displayed a 
similar effect to TNF-to degrade DAPK-1151. However, controversial observations 
were reported that ceramide actually induced DAPK-1 expression. Therefore, more 
experiments are required to elucidate the role of DAPK-1 in the ceramide/TNF- 
signalling pathway.  
 41
1.10 Project aims 
This chapter has highlighted the importance of DAPK-1 in multi-cellular signalling 
pathways and its potential role as a tumour suppressor. The DAPK-1 gene is  
methylated in various tumours and its expression is lost as mentioned in Section 1.6. 
However, the mRNA level of DAPK-1 does not always correlate with its protein 
level. It has been reported that DAPK-1 protein expression can be detected in the 
presence of significant hypermethylation160, suggesting the existence of important 
post-translational mechanism regulating DAPK-1 protein level. Although two 
ubiquitin E3s for DAPK-1 have been identified as mentioned in Section 1.9.3, it is 
still unclear how the ubiquitin-proteasome pathway regulates DAPK-1 and whether 
DAPK-1 is regulated by alternative degradation pathways such as lysosome-
mediated degradation.  
 
It has been published that TNF- induces degradation of DAPK-1151 and DAPK-1 
was found to be cleaved by cathepsin B66. Therefore, it will be the overarching aim 
of this project to investigate the regulation of DAPK-1 by the TNF- signalling and 
cathepsin B degradation pathways.  Specifically, whether cathepsin B is responsible 
for the TNF- induced degradation of DAPK-1,  which domain on DAPK-1 does 
cathepsin B interact with, and how cathepsin B and DAPK-1 regulate TNF-induced 
apoptosis will be addressed. 
 
In addition, splicing is a common event for many genes and results in proteins with 
distinct functions161. A potential splice variant of DAPK-1 exists in the human cDNA 
database, which was indentified from the NEDO human cDNA sequencing project. 
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A secondary aim of this project is to to determine whether this sequence is a DAPK-
1 splice variant. If so, I will determine whether  the splice variant behave similarly to 
DAPK-1, whether it regulates the function or expression of the full-length DAPK-1 


















Figure 1.1 A schematic diagram of the mammalian cell cycle. Cell cycle consists of G1, S, G2 and 
M phases. Two major checkpoints exist between G1/S phases and G2/M phases to ensure the fidelity 
of cell division. G0 is a quiescent stage of cells after mitosis. The length of G0 depends on cell type 




Figure 1.2 A schematic diagram of DAPK-1 structure and its family members15. The numbers 
above the proteins demarcate the amino acid position of each domain. The quantities within the kinase 
domains indicate the degree of amino acid identity to the kinase domain of DAPK-1. Chromosomal 
designations for the human orthologues are also indicated. (Taken from Reference 14)  
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Figure 1.3 A schematic diagram of the CaM regulatory domain of CaMKs and the amino acid 
sequence of the CaM regulatory domain of DAPK-1. The amino acid and number in red signify the 






















Figure 1.4 Schematic reaction of DNA methylation in humans. DNA methylation in humans refers 
to the transfer of a methyl (CH3 group) to cytosine. The reaction is catalyzed by a DNA 
methyltransferase, and uses S-Adenosyl Methionine (SAM) as a methyl donor. During the reaction, 
























Figure 1.5 The four digestive processes mediated by the lysomsome50, including specific receptor-
mediated endocytosis, pinocytosis for non-specific engulfment of cytosolic droplets containing 
extracellular fluid, phagocytosis for bacterium and extracellular particles, microautophagy for 















Figure 1.6 The ubiquitin-proteasome proteolytic system50.  Ubiquitin is activated by the ubiquitin-
activating enzyme, E1 (1) followed by its transfer to a ubiquitin-carrier protein (ubiquitin-conjugating 
enzyme, UBC), E2 (2). E2 transfers the activated ubiquitin moieties to the protein substrate that is 
bound specifically to a unique ubiquitin ligase E3. The transfer is either direct ((3) in the case of 
RING finger ligases) or via an additional thiol-ester intermediate on the ligase ((4, 4a) in case of 
HECT domain ligases). Successive conjugation of ubiquitin moieties to one another generates a 
polyubiquitin chain that serves as the binding (5) and degradation signal for the downstream 26S 
proteasome. The substrate is degraded to short peptides (6), and free and reusable ubiquitin is released 











Figure 1.7 Electron microscopic pictures showing the morphological features of 82 (a) Normal, (b) 
Autophagic, (the most obvious charateristics of which is the accumulation of a lot of visible 
autophagosome bodies as pointed out by red arrows) (c) Apoptotic ( the charateristics of which are 
cell shrinkage,and rounding, cytoplasm condensation, chromatin condensation and fragmentation, and 
importantly a intact plasma membrane) and (d) Necrotic (the most obvrous characteristics of which 
are the breakdown of plasma membrane and vacuolation of the cytoplasm as pointed out by red 









































Figure 1.9 TNF- induced signalling pathways61. The intrinsic pathway disrupts mitochondrial 
membrane potential, leading to the release of cytochrome c, and induction of cell death via caspase 9. 
The extrinsic pathway works through death receptors. Upon TNF- treatment, TNF- binds to TNFR-
1 and promotes recruitment of the complex I composed of TRADD, TRAF2/5, cIAP1/2 and RIP. 
Complex I subsequently activates NF-kB, JNK and p38 pathways to induce the transcription of a 
series of pro-survival factors, which antagonize the apoptosis pathway. When released from TNFR-1, 
complex I can recruit FADD via TRADD and forms complex II, which induces apoptosis through 















Figure 1.10 Signalling pathways leading to autophagy106.  Two ubiquitin-like conjugation systems 
lead to autophagy. In one system, Atg12 is activated by Atg7 and transferred to Atg5 by Atg10. The 
Atg5-Atg12 complex interacts with Atg16 on the membrane of early autophagosome and is released 
after the maturation of the autophagosome. In the other system, Atg8/LC3 is transferred to PE by 
Atg7 and Atg3. The Atg8/LC3-PE complex is localized to the autophagosomal membrane by the 
Atg5-Atg12-Atg16 complex and stays on the membrane of mature autophagosome until it is degraded 


























Figure 1.11 Examples of membrane blebbing133. (A) Myosin light chain localization in a filamin-
deficient melanoma cell. Myosin (in green) localizes to distinct puncta under the blebbing membrane 
(in red). (B) Scanning electron microscopy image of a filamin-deficient melanoma cell. Blebs can 
clearly be seen over the entire cell surface. Most blebs are spherical, others have elongated into 




Figure 1.12 The bleb cycle133. The life cycle of blebbing can be divided into three phases: bleb 
initiation, expansion and retraction. (a) Bleb initiation can result from a local detachment of the cortex 
from the membrane (left) or from a local rupture of the cortex (right). (b) Hydrostatic pressure in the 
cytoplasm (Pint) then drives membrane expansion by propelling cytoplasmic fluid through the 
remaining cortex (left) or through the cortex hole (right). Concomitantly, the membrane can detach 
further from the cortex, increasing the diameter of the bleb base (dashed line). (c) As bleb expansion 
slows down, a new actin cortex reforms under the bleb membrane. (d) Recruitment of myosin to the 





























Figure 1.13 A schematic diagram of the phosphorylation sites on DAPK-1. In addition to the 
autophosphorylation site at Ser308, DAPK-1 can also be phosphorylated by RSK at Ser289, Src at 
Tyr491/492 and ERK at Ser735. Moreover, LAR can specifically dephosphorylate DAPK-1 at 
Tyr491/492, thus playing a reciprocal role to Src.  
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Chapter Two Materials and Methods 
2.1 General materials 
All reagents were supplied by Sigma unless otherwise stated. All oligonucleotides 
were synthesized by Sigma-Genosys. All siRNA were ordered from Dharmacon. All 
restriction enzymes were supplied by New England Biolabs.  
 
PCDNA3.1 plasmid was from Invitrogen. HA-DAPK-1 vector was a gift from Adi 
Kimchi (Weizmann Institute, Israel), TNFR-1 vector was a gift of Vishva Dixit 
(Genentech), and cathepsin B-GFP plasmid was a gift from Antonio Baici 
(University of Zurich). The plasmids for cloning will be described in section 2.4.5. 
The plasmids for site direct mutagenesis will be described in section 2.4.6.  
 
For tissue culture, Foetal bovine serum (FBS), Dulbecco’s modified eagles’s medium 
(DMEM), Roswell Park Memorial Institute (RPMI-1640) medium, McCoy’s 5A 
medium and trypsin-EDTA solution were supplied by Gibco-BRL. All the other 
materials needed for specific experiments will be addressed in the appropriate 
sections.  
2.2 Transformation and plasmid maintenance  
2.2.1 Preparation of competent cells 
Glycerol stocks of the required E.Coli bacterial strain DH5 or BL21 were 
inoculated into 3ml Luria-Bertani (LB) medium (1% w/v Tryptone, 0.5% w/v Yeast 
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extract, 1% w/v NaCl and sterilized by autoclaving at 121oC for 20 minutes) and 
allowed to grow overnight at 37oC. 250l of the overnight culture were transferred 
into 50ml LB and incubated at 37oC until the O.D.600nm of the culture reached 
approximately 0.4. Cells were collected by centrifugation at 1800g for 15 minutes at 
4oC, resuspended gently in 16ml ice-cold Buffer 1, pH5.8 (1.2g RbCl, 0.99g 
MnCl2·4H2O, 0.59g CH3COOK, 1.5g CaCl2·2H2O and 15% v/v glycerol in 100ml 
distilled H2O) and left on ice for 10 minutes. Then the cells were centrifuged again at 
1800g for 15 minutes at 4oC and gently resuspended in 2ml ice-cold buffer 2, pH6.8 
(10mM MOPS pH6.8, 0.12g RbCl, 1.1g CaCl2·2H2O and 15% v/v glycerol in 100ml 
distilled H2O). After 10-minute incubation on ice, the cells were aliquoted and snap-
frozen in liquid nitrogen and stored at -80oC.  
 
2.2.2 Heat shock transformation 
An aliquot of competent cells was incubated on ice with equal amount of 1X KCM 
(100mM KCl, 30mM CaCl2 and 50mM MgCl2) and appropriate amount of plasmid 
(usually 50ng) for 30 minutes. The cells were then subject to heat shock by 
incubating at 42oC for 45 seconds and left at room temperature for 10 minutes. LB 
medium was added to the competent cell/plasmid mixture and cultured for 1 hour at 
37oC to allow the growth of transformed bacteria cells. Finally the cells were plated 
onto pre-prepared LB agar plates with selection antibiotics specific for the plasmid 
transformed and the plates were incubated at 37oC overnight for colony formation.   
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2.2.3 Plasmid maintenance 
After transformation, single colonies were selected and allowed to grow overnight at 
37oC either in 5ml LB medium for mini-prep or 150ml LB medium for maxi-prep. 
Before purification, for the plasmids that are transformed for the first time, 750l of 
the transformed-cell culture were mixed with 250l of glycerol and stored at -80oC. 
Future culture to obtain these plasmids can then avoid the transformation step and 
start directly from the inoculation of these glycerol stock. To purify plasmids from 
culture, mini-prep or maxi-prep were carried out using the high speed mini-prep or 
maxi-prep kits from Qiagen following the manufacturer’s protocols. Concentration 
of the plasmids was measured by ND-3300 Fluorospectrometer (NanoDrop 
Technologies) at 260nm. Purified plasmids are stored at -20oC.  
 
2.3 Tissue culture and transient transfection 
2.3.1 Cell maintenance and sub-culture 
Hela (human cervix epithelial carcinoma), A549 (human alveolar epithelial cell), 
HEK293 (Human embryonic kidney cell line) and A375 (human melanoma) cells 
were cultured in DMEM, H1299 (human lung carcinoma) cells were cultured in 
RPMI medium, and HCT116 (human colon carcinoma) cells were cultured in 
McCoy’s 5A medium. The medium were supplemented with 10% FBS and a 
penicillin and streptomycin mixture from Gibco at 37 °C with 5% CO2 in a 
humidified atmosphere.  
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Cells were usually maintained in 175cm2 flasks and sub-cultured into different 
containers dependent on the requirement of individual experiment. When confluent, 
cells were rinsed with 3ml of PBS twice, followed by the addition of 3ml trypsin-
EDTA solution/175 cm2 flask and incubated at 37oC. After all the cells floated, 7ml 
medium with FBS were added per 175 cm2 flask to stop the reaction. The trypsinised 
cells were then centrifuged at 400g for 1 minute and a portion of the collected cells, 
which is dependent on the growth rate of individual cell line, was resuspended with 
fresh medium in a new flask.  
 
In a typical experiment, 106 cells were sub-cultured into a 10cm tissue culture plate 
and left for at least 24 hours to attach to the bottom of the container. Before 
harvesting, cells were first washed twice with PBS and then scraped into 1ml of PBS.  
 
2.3.2 Long-term storage of cells 
For long-term cell storage, a 175cm2 flask of cells were trypsinised and collected as 
mentioned in 2.3.1 and resuspended in 5 ml of freezing solution composed of 4ml 
FBS and 1ml Demethyl sulfoxide (DMSO). The cell solution was then aliquoted into 
5 cell storage vials, left at -80oC overnight and kept in liquid nitrogen the next day.  
 
In order to recover a frozen cell culture stock, a vial of cells was rapidly thawed at 
37oC in water bath and transferred into a 15ml centrifuge tube with 10ml fresh 
medium. The cells were then collected by centrifugation at 400g to remove DMSO 
and resuspended with fresh medium in a 175cm2 flask.   
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2.3.3 Cell treatments 
In order to induce the required response, cells were treated with certain reagents or 
cultured with serum free medium. In most cases, reagents were added directly onto 
the cells. In experiments requiring medium change, cells were first washed twice 
with serum free medium and then cultured in medium containing certain reagents or 
serum free medium. The reagents used in cell treatments were listed in Table 2.1. 
 
Table 2.1 Reagents used in cell treatments.  
















































2.3.4 Transient transfection 
All transfections were carried out by the liposome-mediated method using 
Lipofectamine 2000 based on the manufacturer’s guide. In plasmid transfection, the 
exact quantity of transfected plasmid varied in each experiment and was dependent 
on the expression of individual plasmid. However, in each experiment, carrier 
plasmid such as PCDNA3.1 was co-transfected to keep the quantity of transfected 
plasmid consistent in each transfection.  In siRNA transfection, the amount of siRNA 
used depended on the volume of the cell culture medium because a certain 
concentration of siRNA is compulsory to maintain its activity. Usually 100nM was 
the final concentration used in the siRNA transfection experiment.  
 
2.4 DNA and mRNA assays 
2.4.1 mRNA extraction  
mRNA was extracted from cells and tissues using the Qiagen RNeasy Mini kit 
following the manufacturer’s suggested procedures. The optional step of DNase 
treatment using the Qiagen RNase-free DNase set was also included. The 
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concentration of the extracted mRNA was measured by ND-3300 
Fluorospectrometer (NanoDrop Technologies) at 260nm. 
 
2.4.2 Reverse Transcription (RT) Polymerase Chain Reaction (PCR) 
RT of mRNA was performed using the Omniscript RT kit from Qiagen following the 
manufacturer’s suggested protocols. The PCR of the reverse-transcribed cDNA was 
performed using the pfu polymerase kit from Stratagene according to manufacturer’s 
suggestions. The primers for RT PCR are listed in Table 2.2. 
Table 2.2 Primers for RT PCR.  
s-DAPK-1 RT PCR primers  
Forward: 5’-ATGGCCCTCCACGTGGCAGCTCGCTA-3’ 
Reverse:  5’-CTAAGGCCACAGGGTCCAGTATAGGC-3’ 
 
2.4.3 Agarose gel electrophoresis 
DNA samples were mixed with 6X DNA loading buffer (30% v/v glycerol, 0.6% w/v 
SDS, 60mM EDTA and 0.1% w/v bromophenol blue) before loading on the gel. 
Agarose gels were created by dissolving agarose in heated 1X Tris/Borate/EDTA 
(TBE) buffer (90mM Tris, 90mM Boric acid and 2mM EDTA). The percentage of 
agarose in gel depended on the size of sample DNA. As a size reference, a DNA 
marker from Invitrogen was loaded next to the DNA samples. Electrophoresis was 
performed at 100V until a good resolution was observed under a UV transilluminator. 
The images of the gels were captured using the ChemiGenius2 Bio-Imaging system 
from Syngene.    
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2.4.4 Real-time PCR 
Real time PCR was performed using the Qiagen QuantiTect SYBR Green one-step 
PCR kit following the manufacturer’s suggested protocols. The primers used in real-
time PCR were designed by Primer3162 software and listed in Table 2.3.  
 
Table 2.3 Primers for real-time PCR.  
DAPK-1 real-time primers     
Forward: 5’-CGAGGTGATGGTGTATGGTG-3’ 
Reverse:  5’-CTGTGCTTTGCTGGTGGA-3’ 
s-DAPK-1 real-time primers    
Forward: 5’-CGTCTCTCCAGCAGGTGTT-3’  
Reverse:  5’-TAAGGCCACAGGGTCCAGTA-3’ 
Actin real-time primers    
Forward: 5’-CTACGTCGCCCTGGACTTCGAGC-3’ 
Reverse:  5’-GATGGAGCCGCCGATCCACACGG-3’ 
 
2.4.5 Cloning 
In order to clone certain DNA into the required expression vector, two cloning 
techniques were used. For the cloning of GST-836-947 and GST-s-DAPK-1, 
Gateway cloning was performed using the Gateway® Cloning kit from Invitrogen 
following the manufacturer suggested protocols. pDEST27 vector (Figure 2.1) for 
mammalian cell expression was the destination vector for GST-836-947, whilst 
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pDEST15 vector (Figure 2.1) for bacterial expression was that for GST-s-DAPK-1. 
The primers for Gateway cloning were listed in Table 2.4.  
Table 2.4 Primers for gateway cloning.  
GST-836-947 Gateway cloning primers 
Forward: 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATCCATGT 
TGTTGTCTTTAGTCTAGAA-3’ 
Reverse:  5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAATTTCG 
AAGTACCTTCATGTCCTTTGA-3’ 
GST-s-DAPK-1 Gateway cloning primers 
Forward: 5’-GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGCCCT 
CCACGTGGCAGCTCGCTA -3’ 
Reverse:  5’-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAAGGCCA 
CAGGGTCCAGTATAG -3’ 
 
For the cloning of s-DAPK-1 into 3XFlag-Myc-CMV-26 expression vector (Sigma) 
and into pAcGFP-C1 vector (Clontech), traditional cloning techniques were applied 
by performing RT PCR of s-DAPK-1 and restriction enzyme digestion. For Flag-s-
DAPK-1-Myc cloning, EcoR I and Xba I restriction sites were included in the 
primers; whilst for GFP-s-DAPK-1, EcoR I and Sal I restriction sites were included. 
The primers for normal cloning are listed in Table 2.5. In a typical cloning reaction, 
the vectors and PCR product were digested with the same restriction enzymes before 
agarose gel electrophoresis. The single strand digested bands observed on gel were 
then purified using the Gel Purification kit from Qiagen. After purification, the 
digested vector and PCR product were applied for ligation overnight using the T4 
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DNA ligation kit from Promega. In the end, heat shock transformation of the ligation 
mixture with competent DH5- cells was performed to select the vector with the 
PCR product cloned into it.  
Table 2.5 Primers for normal cloing.  
Flag-s-DAPK-1-Myc Cloning primers 
Forward: 5’-TTGAATTCAATGGCCCTCCACCGTGGCAGCT-3’ 
Reverse:  5’-TTTCTAGAAGGCCACAGGGTCCAGTATAG-3’ 
GFP-s-DAPK-1 cloning primers 
Forward: 5’-TTGAATTCGATGGCCCTCCACGTGGCAGCTCGCTA-3’ 
Reverse:  5’-TTGTCGACCTAAGGCCACAGGTCCAGTATAGGC-3’ 
 
2.4.6 Site-directed mutagenesis 
In order to create certain mutations on specific sites of plasmid, QuickchangeTM Site-
Directed Mutagenesis kit from Stratagene was used to create all the mutants on HA-
DAPK-1, Flag-s-DAPK-1-Myc and GFP-s-DAPK-1 based on the manufacturer’s 
provided protocols. The deletion mutants were generated by inserting stop codons at 
the respective sites. Primers for site-directed mutagenesis were designed using the 
PrimerX163 software and listed in Table 2.6.  
Table 2.6 Primers for site-directed mutagenesis.  
HA-DAPK-1 mutation primers 




Primers for HA-1-641 
Forward: 5’-CTGACCACGGACGGATAGACGGCAGAAGATC-3’ 
Reverse: 5’-GATCTTCTGCCGTCTATCCGTCCGTGGTCAG-3’ 










Primers for HA-1-1313     
Forward: 5’-CACTCGGAGGAAATAGAGTCGCCTGCTGG-3’   
Reverse: 5’-CCAGCAGGCGACTCTATTTCCTCCGAGTG-3’ 
Flag-s-DAPK-1-Myc and GFP-s-DAPK-1 mutation primers 
Primers for Myc deletion mutant Flag-s-DAPK-1  
Forward: 5’-CTGGACCCTGTGGCCTTAGAGAGAACAAAAACTCATC-3’ 
Reverse: 5’-GATGAGTTTTTGTTCTCTCTAAGGCCACAGGGTCCAG-3’ 
Primers for tail deletion (TD) mutant Flag-TD and GFP-TD 
Forward: 5’-GGCTTCTAAGCCCACATGAAGGAACCTCCATGCTG-3’ 
Reverse: 5’-CAGCATGGAGGTTCCTTCATGTGGGCTTAGAAGCC-3’ 






Primers for tail mutation (TM) mutant 1 Flag-TM1 and GFP-TM1 
Forward: 5’-CTTCTAAGCCCACAGCTGCGAACCTCCATGCTGGC-3’ 
Reverse: 5’-GCCAGCATGGAGGTTCGCAGCTGTGGGCTTAGAAG-3’ 





Primers for Flag-TM3 
Forward: 5’-CAGGTAGGAACCTCGCTGCTGGCCCCGTC-3’ 
Reverse: 5’-GACGGGGCCAGCAGCGAGGTTCCTACCTG-3’ 





Primers for Flag-TM5 
Forward: 5’-CATGCTGGCCCCGCAGCTCCAGCAGGTG-3’ 
Reverse: 5’-CACCTGCTGGAGCTGCGGGGCCAGCATG -3’ 
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2.4.7 DNA sequencing 
Automated sequencing was carried out by the DNA sequencing service in Genetics 
Core, WTCRF, University of Edinburgh, Western General Hospital, Edinburgh, UK.   
 
2.5 Protein assays 
2.5.1 Protein extraction from cells 
In a typical experiment as described in section 2.3.1, after being collected, the cells 
were centrifuged at 400g for 1 minute and the supernatant was removed. The cell 
pellet was lysed in approximately 4 times volume of lysis buffers. Two lysis buffers 
were used. One is the Nonidet-P (NP)40 lysis buffer (1% v/v NP40, 150mM NaCl, 
25mM Tris pH 7.5, 1mM Dithiothreitol (DTT) and 1X protease inhibitor) and the 
other is the Urea lysis buffer (7 M UREA, 100mM DTT, 50mM Hepes pH 8.0, 
25mM NaCl and 0.05% v/v Triton X-100). NP40 lysis buffer was applied in regular 
experiment and Urea lysis buffer for experiments required to extract insoluble 
proteins considering its much harsher extracting ability.  
 
2.5.2 Determination of protein concentration 
1X Bradford reagent was prepared by dissolving 100mg Coomassie Blue in 50ml 
95% ethanol, 100ml 85% phosphoric acid and 850ml distilled H2O, stored at 4
oC, 
and filtered using a syringe and 0.45M filter (Millipore) before use. 1l protein 
sample was mixed with 1ml of 1X Bradford reagent, vortexed and incubated at room 
temperature for 5 minutes to develop colour reaction. The absorbance of the mixture 
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was tested at 595nm in a disposable cuvette using a spectrometer. The protein 
concentration was calculated using a Bovine Serum Albumin (BSA) standard curve. 
40g of each sample is usually loaded on the gels for a typical western experiment. 
When the expression of the interested protein is too high or too low, the respective 
amount of protein loaded on the gel is reduced or increased according to individual 
experiment.   
 
2.5.3 Western Blot 
Western blot was composed of two main steps: Sodium Dodecyl Sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) and immunoblotting. In SDS-PAGE, 
equal amount of protein samples were first mixed with 4X SDS sample buffer (4% 
w/v SDS, 25mM Tris pH 6.8, 20% v/v glycerol, 0.01% w/v bromophenol blue and 
200mM DTT) and incubated at 95oC for 2 minutes before loading onto 8, 10, 12 or 
15% polyacrylamide gel or 4-12% NuPAGE Bis-Tris gel (Invitrogen). The selection 
of gels depends on the respective experiments. The running gel of polyacrylamide 
gel is composed of 25% 1.5M Tris pH8.8, 0.1% SDS, 0.1% w/v Ammonium 
Persulfate (APS), v/v 0.04% Tetramethylethylenediamine (TEMED) and required 
amount of 30% w/v acrylamide mixture from National Diagnostics. The stacking gel 
of polyacrylamide gel is composed of 1/12 1M Tris pH 6.8, 0.1% w/v SDS, 0.1% 
w/v APS, 0.1% v/v TEMED and 1/6 of 30% w/v acrylamide mixture. The samples 
on polyacrylamide gels were resolved by electrophoresis in SDS running buffer 
(0.1% w/v SDS, 0.192M glycine and 25mM Tris) on BioRad mini-protean 3 
apparatus. The samples on 4-12% NuPAGE Bis-Tris gels were resolved by 
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electrophoresis in MOPS buffer (Invitrogen) on a Novex XCell SurelLock gel 
apparatus.  
 
For immunoblotting, the resolved proteins were first transferred onto Hybond-C 
nitrocellulose membrane (Amersham Biosciences) in transfer buffer (0.192M glycine, 
25mM Tris and 20% v/v methanol) on BioRad transfer kit at 350mA for 2 hours. An 
ice pack was placed in the transfer tank to maintain low temperature to help protein 
transfer.  
 
Following transfer, the membrane was incubated in PBS-Tween-20 (0.1% v/v 
Tween-20 in PBS) (PBST) with 5% w/v dry skimmed milk (MARVEL) for 1 hour at 
room temperature to block non-specific protein binding. Then after a quick wash 
with PBST, the membrane was incubated with the primary antibodies at a supplier-
recommended dilution in PBST with milk and shaken at 4oC overnight. The next 
morning the blot was washed 3 times for 5 minutes with PBST and incubated with 
respective horse radish peroxidase (HRP) coupled secondary antibodies from DAKO 
in PBST with milk to detect specific antibody binding. Finally the blot was washed 3 
times with PBST for 5 minutes and then incubated with electrochemiluminescence 
(ECL) solution mixture. ECL solution I was composed of 2.5mM luminol, 0.4mM 
coumaric acid and 100mM Tris pH 8.5, and ECL solution II composed of 100mM 
Tris pH8.5 and 0.018% v/v H2O2 (BioRad). ECL solutions were kept in the dark at 
4oC and mixed at 1:1 ratio prior to incubation with the blot. Specific bands were 
detected by exposing the membrane to ECL hyperfilm (Amersham Biosciences). The 
primary antibodies used were listed ini Table 2.7. The blot data was quantified by 
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densitometry using Scion Image Software (National Institues of Helath) and 
normalised to the level of the control protein.  
Table 2.7 Primary antibodies used in western blot.  
Antibody name Source Company Dilution
Cathepsin B antibody sheep Serotec 1:1000 
DAPK-1 antibody mouse BD Bioscience 1:250 
DAPK-1 antibody (55) mouse Santa Cruz Biotechnology 1:1000 
DAPK-2 antibody goat Santa Cruz Biotechnology 1:1000 
DAPK-3 (ZIP) antibody goat Santa Cruz Biotechnology 1:1000 
Flag antibody mouse Sigma 1:5000 
GFP antibody mouse Cancer Research UK 1:1000 
GST antibody mouse Sigma 1:1000 
HA.11 antibody mouse Covance  1:1000 
IRF-1 antibody mouse BD Bioscience 1:1000 
p53 antibody (DO1) mouse Moravian Biotechnology  1:1000 
PARP antibody rabbit Cell Signalling 1:1000 
TNFR-1 antibody goat Santa Cruz Biotechnology 1:1000 
 
2.5.4 Fractionation 
One 106 plate of cells was used for each fractionation. The fractionation samples 
were extracted using the ProteoExtract® Subcellular Proteome Extraction Kit from 
Calbiochem in accordance to the manufacturer’s protocols. 
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2.5.5 Immunoprecipitation (IP) 
Protein G SepharoseTM 4 Fast Flow or Glutathione-SepharoseTM from GE Healthcare 
were used in IP reactions. The beads were kept in 70% ethanol in a 1:1 ratio. Each 
reaction required 25l of beads, and before the immunoprecipitation, the beads were 
washed 5 times with 1 ml of IP dilution buffer (0.1% v/v NP40, 25mM Tris pH 7.5, 
150mM KCl, 1mM DTT, and 1X complete mini protease inhibitor from Roche 
Diagnostics). Proteins for IP were extracted by lysing the cells with NP40 lysis 
buffer described in section 2.5.1. Equal amounts of proteins were added to 1 ml of IP 
dilution buffer. After that, the antibodies for IP and protein G beads in suspension 
were added into the tubes, and the mixture was rotated overnight at 4 °C. After 
rotation, the beads were sedimented at 1200g and the supernatants were discarded. 
The beads were then washed six times by rotating them in 1 ml of IP dilution buffer 
for 5 min at room temperature. In the end, proteins bound to the beads were either 
eluted using elution buffers or extracted directly by adding 4X SDS sample buffer.  
 
2.5.6 In vitro synthesis of radioactive protein 
35S-labelled protein was synthesized using the TNT® translation kit (Promega) 
following to the manufacturer’s protocols.  
 
2.5.7 In vitro cleavage of radioactive HA-DAPK-1 by cathepsin B 
35S-labeled HA-DAPK-1 was synthesized as described in section 2.5.6. 2l of the 
35S-labeled HA-DAPK-1 was added to 5l of 3X cathepsin B reaction buffer 
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(150mM sodium acetate, pH 6.0, 12mM EDTA and 24mM DTT) with 1l of 
purified cathepsin B (0.02 units/l, U.S. Biological), which was diluted in 50mM 
sodium acetate pH 5.0 with 1mM EDTA prior to use. The final volume of the 
reaction was brought to 15l with distilled water. The cleavage reaction was 
performed by incubation at 37 °C for indicated time. After incubation, 15l of 4X 
SDS sample buffer was added to the samples, and then were boiled and subjected to 
SDS-PAGE. The gels were then dried, and the signals were detected by 
autoradiography. 
 
2.5.8 Protein purification from bacterial expression system 
Bacteria BL21 cells were transformed as described in section 2.2.2 with the plasmid 
that is designed for bacterial expression, e.g. pDEST15 (Figure 2.1) from Invitrogen, 
and cultured in 10ml LB medium with 100M ampicillin overnight. The next day the 
transformed bacteria culture was inoculated into 500ml LB medium with 100M 
ampicillin and incubated for approximately 3 hours until the O.D.600nm of the culture 
reached 0.6. The culture was then incubated with 0.2% w/v Arabinose for another 3 
hours and lysed with 0.2% Triton in PBS. The synthesized protein was then purified 
from the lysate by IP as mentioned in 2.5.5.  
 
2.5.9 In vitro cleavage of recombinant GST-s-DAPK-1 by cell lysate 
GST-s-DAPK-1 was synthesized as mentioned in 2.5.8 and purified from the lysate 
by IP using glutathione-SepharoseTM, and eluted with 50mM Glutathione in PBS, 
pH8.0. For in vitro cleavage assay, 2μl of the purified GST fusion protein were 
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incubated at 30oC with indicated amount of NP40 cell lysis for 30 minutes. The 
reaction was then stopped by adding 4X SDS sample buffer and the mixture was 
subject to western blot. 
 
2.6 Immunofluorescent assays 
2.6.1 Fluorescent microscopy  
For normal protein localization assay, cells were seeded on NUNC LAB-TEK® 4-
well chamber slides at a density of approximately 5x104 cells/well. 18 hours later, 
cells were transfected with the indicated expression vectors for a further 24 hours. 
Then the slides were washed in 1X PBS and fixed in 4% paraformaldehyde for 15 
minutes at room temperature and washed three times in 1X PBS afterwards. The 
cells were fixed in ice-cold methanol for 5 minutes and air-dried. After that, cells 
were permeabilized in freshly prepared 0.5% w/v Triton X-100 in 1X PBS, and 
slides were washed three times with 1X PBS for 10 minutes. Following washes with 
1X PBS, non-specific sites were blocked for 1 hour with 3% w/v BSA/PBS at room 
temperature. After three washes in 1X PBS, the chambers from each slide were 
removed, and cells were incubated overnight with the primary antibody diluted in 1% 
v/v BSA/PBS at 4°C. 24 hours post-incubation, the slides were washed in 0.1% v/v 
PBS-Tween and incubated with the Alexa dye conjugated secondary antibodies from 
Invitrogen, which are listed on Table 2.8, for 30 minutes at room temperature. After 
incubation, cells were washed three times in 1X PBST. Nuclei were counterstained 
with Topro-3 from Invitrogen. Coverslips were mounted with Fluorescent mounting 
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medium (DakoCytomation). The control for non-specific binding of the secondary 
antibody was the 1% w/v BSA/PBS, where no primary antibody was added.  
Table 2.8 Secondary antibodies for immunofluorescence.  
Secondary antibody name Colour Dilution 
Alexa 488 Goat anti mouse Green 1:100 
Alexa 488 Donkey anti rat Green 1:100 
Alexa 568 Goat anti rabbit Red 1:100 
 
Microscopy analysis was performed on Zeiss microscope (Zeiss Axionplan Imaging 
Systems provided by the Medical Research Council, Human Genetics Unit). The 
photometric CoolSnap HQ camera was used to capture the image.  
2.6.2 TUNEL apoptosis assay 
Cells were seeded directly onto coverslips in 6-well plates. 18 hours later cells were 
transfected with indicated amounts of expression vectors for a further 24 hours. 
Following transfection, cells were fixed in 1% paraformaldehyde for 10 minutes at 
room temperature. Apoptotic cells were labelled using Apoptag Plus fluorescein in 
situ apoptosis detection kit S7111 (Chemicon International) according to the 
manufacturer’s instructions and viewed by fluorescent microscopy. 
 
2.6.3 Membrane blebbing assay 
Cells for membrane blebbing were seeded and transfected as described in section 
2.6.1. 24 hours post transfection, cells were fixed with 4% paraformaldehyde in 1X 
PBS for 10 minutes, washed with 1X PBS for 3 times and blocked with 3% w/v 
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BSA/PBS for 1 hour. Then after incubation with the appropriate primary antibodies 
for 1h, cells were washed 3 times with 1X PBS and stained with the appropriate 
fluorescent secondary antibody for 1 hour before being mounted and ready for 
observation for membrane blebbing morphology using Zeiss microscope.  
2.7 Annexin V staining assay 
Cells were seeded into 6 well plates. 18 hours later, cells were transfected with the 
indicated amounts of expression vectors for a further 24 hours. In order to include 
any floating cells, medium was collected into fluorescence-activated cell sorting 
tubes and centrifuged at 360g for 4 minutes to leave a cell pellet. Medium was then 
discarded from tubes. Plates were then washed once with 2 ml of PBS and 1.5 ml of 
trypsin was added to each plate and incubated until cells became detached. Following 
cell detachment, 1.5 ml of McCoy’s 5A medium supplemented with 10% FBS was 
added to each plate to stop the trypsin. The cell suspensions were then added to each 
of the relevant cell pellets from the floating cells. Samples were centrifuged at 360g 
for 4 min, and pellets were resuspended in 1 ml of McCoy’s 5A medium 
supplemented with 10% FBS and incubated for 5 min. Samples were centrifuged for 
a further 4 min at 360g prior to resuspension in 1ml of ice-cold 1X PBS. Apoptotic 
cells were detected using a TACSTM Annexin V-fluorescein isothiocyanate apoptosis 
detection kit (R&D systems) according to the manufacturer’s instruction and 









Figure 2.1 Schematic maps of pDEST15 and pDEST27 vectors. (Taken from Invitrogen website) 
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Chapter Three Regulation of TNF- mediated 
apoptotic pathway by DAPK-1/cathepsin B complex 
3.1 Introduction 
DAPK-1 is a member of the CaMK superfamily that includes CHK2 and AMPK. 
Recent studies highlighted that these kinases play a genetic role in activating the p53 
tumour suppressor pathway132. Down-regulation of DAPK-1 by CpG methylation 
has been shown in a variety of tumours, providing tumours with growth advantages15. 
Moreover, a recent study revealed that DAPK-1 is a transcriptional target of p53157. 
Thus the fact that DAPK-1 is linked to the control of p53 expression by 
phosphorylation132 and DAPK-1 itself is a transcriptional target of p53 indicates that 
a feedback loop exists between DAPK-1 and p53. These data suggest that 
transcriptional regulation of DAPK-1 is important for its function. However, the 
protein levels of DAPK-1 do not always correlate with the level of mRNA 
expression46, 160, 164, therefore, additional mechanisms are important for the control of 
DAPK-1 activity.  
 
Growing evidence suggests that some post-translational mechanisms control the 
activity of DAPK-1 in cells15, 47, 62, 66. These include RSK-dependent inactivation of 
DAPK-1, ERK dependent activation of the proapoptotic function of DAPK-1, DIP-1 
dependent ubiquitination and proteasomal degradation of DAPK-1 and cathepsin B 
dependent cleavage of DAPK-1. In addition, a study in renal cell carcinomas 
demonstrates that the enzyme activity of DAPK-1 in these cells is largely attenuated 
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although its mRNA and protein are highly expressed47. Therefore, post-translational 
modification of DAPK-1 seems to be very important for its function.  
 
The aim of this part of my project is to investigate how the steady state level of 
DAPK-1 protein is regulated, and characterize new factors that can control DAPK-1 
protein stability. It has been reported that TNF- can induce the proteasomal 
degradation of DAPK-1151. Therefore, I focused on identifying factors important for 
TNF- induced DAPK-1 degradation. Furthermore, the role played by DAPK-1 in 
the TNF- induced apoptotic pathway, i.e. a positive or negative regulator, is 
somewhat controversial. Therefore this will also be investigated in my study.  
 
3.2 Uncoupled DAPK-1 protein level from gene expression 
In tumour cell lines with a defined p53 status, we set up experiments to determine 
whether DAPK-1 protein expression was controlled post-translationally. The mRNA 
and protein expressions of DAPK-1 in six different tumour cell lines were examined 
(Figure 3.1). In HCT116 cells, DAPK-1 protein is expressed in both p53 wild type 
(+/+) and p53 null (-/-) cells (Figure 3.1), whereas in Hela cells, which have an HPV-
E6 attenuated wild type p53 pathway, DAPK-1 levels are relatively high (Figure 3.1). 
These data suggest that the basal expression of DAPK-1 protein is not p53-dependent, 
which is consistent with previous work157. More interestingly, Hela cells actually 
possess more DAPK-1 protein compared with A549 cells, which have the highest 
mRNA level (Figure 3.1). This indicates that DAPK-1 can be regulated post-
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translationally, and this regulation may be important for determining the basal 
protein levels of DAPK-1.  
 
DAPK-1 was initially defined as a factor in interferon--induced apoptotic pathway8. 
Therefore, cells were treated with the virus mimetic reagent pIpC 
(polyinosinic:polycytidylic acid), which is structurally similar to double-stranded 
RNA and can interact with toll like receptor 3 (TLR3) to activate interferon 
responsive pathway, to determine whether it can trigger transcriptional or post-
translational changes in DAPK-1. The stress-induced expression of a series of 
endogenous proteins, including interferon-responsive factor-1 (IRF-1) and DAPK-1 
were examined (Figure 3.2A). The IRF-1 level increased as expected, but there were 
no significant changes in the steady-state expression of any DAPK family members 
or p53.  
 
HCT116 p53+/+ and HCT116 p53-/- cells were then treated with combined serum 
starvation and pIpC treatment, because the cells respond better to these combined 
stresses as reported previously126. Upon serum starvation or pIpC treatement, DAPK-
1 mRNA levels decreased by around 50% in the HCT116 p53+/+ cells (Figure 3.2B). 
Combinational treatment caused a further decrease in DAPK-1 mRNA level in 
HCT116 p53+/+ cells (Figure 3.2B), implicating a synergy between these two 
signals in regulating DAPK-1 transcription. However, despite the changes in mRNA 
levels, the DAPK-1 protein levels remained the same with or without treatment in 
HCT116 p53+/+ cells (Figure 3.2B), suggesting again that gene transcription is not 
the key for reguatling DAPK-1 protein levels in cancer cell lines.  
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Simiarly, in HCT116 p53-/- cells, although DAPK-1 mRNA level was reduced upon 
pIpC treatement, its protein levels remained the same. Interestingly, serum starvation 
didn’t change the DAPK-1 mRNA level in HCT116 p53-/- cells, which suggested 
that factors in the serum may induce DAPK-1 mRNA expression through p53 and 
supported the idea that p53 can induce DAPK-1 expression in response to stress157.  
 
3.3 Stability and cleavage of DAPK-1 protein 
The stability of DAPK-1 protein was subsequently examined in Hela cells where 
DAPK-1-dependent signalling pathways operate, by performing a time course of 
cycloheximide, which inhibits the general protein translation machinery. Surprisingly, 
DAPK-1 protein level increased after 6h cycloheximide treatment (Figure 3.3), 
suggesting some regulatory proteins for degrading DAPK-1 may be highly unstable 
and get depleted very quickly after the treatment of CHX, resulting in the 
accumulation of DAPK-1 protein. These data suggest that DAPK-1 protein might be 
stored or assembled into a stable and possibly latent multiprotein complex in cells, 
since it is not rapidly degraded and resynthesized.  
 
The stability data are in contrast to a previous report demonstrating that DAPK-1 can 
be controlled post-translationally via a proteasome-dependent pathway that involves 
the E3 ubiquitin ligase DIP-162, since usually proteasome regulates short half-life 
proteins50. Therefore I tested the effect of the proteasome inhibitor MG132 on 
steady-state levels of endogenous DAPK-1 to determine whether DAPK-1 protein 
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can be turned over by a proteasome-dependent pathway, despite the fact that it has a 
relatively high stability. MG132 treatment did increase the DAPK-1 protein levels 
and rendered higher molecular mass adducts, which might be ubiquitinated DAPK-1 
(Figure 3.4A, lane 2 versus lane 1). However, as highlighted by the arrows, MG132 
also unexpectedly depleted some lower mass fragments of DAPK-1. This suggests 
that DAPK-1 protein is actively cleaved in cells by a protease(s) that can be inhibited 
by MG132.  
 
Several previous reports have described the appearance of DAPK-1 protein cleavage 
products65, 66. These reports are consistent with our data showing that DAPK-1 is 
cleaved by some proteases in vivo. Recently it was reported that the accumulation of 
a 60-kDa cleavage band of DAPK-1 protein is specifically inhibited by a cathepsin B 
inhibitor66. Moreover, since MG132 can also function as a general inhibitor of 
cathepsins165, we compared the effect of cathepsin B inhibitor with MG132 on 
inhibition of the cleavage of DAPK-1. The cathepsin B inhibitor depleted similar 
cleavage products as observed using MG132 (Figure 3.4B), albeit to a lesser extent, 
which possibly reflects the efficacy of the inhibitors.  
 
3.4 Interaction of DAPK-1 and cathepsin B 
In order to confirm that cathepsin B is able to cleave DAPK-1, radioactive labelled 
DAPK-1 protein was incubated with purified cathepsin B protein in vitro and a 
60KDa cleavage product was also observed (Figure 3.5), suggesting that cathepsin B 
but not the proteasome is responsible for the accumulation of lower mass adducts 
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seen in cells. Since cathepsin B and DAPK-1 appear to interact in vivo, as defined by 
cathepsin B-sensitive proteolytic fragments (Figure 3.5), we set out to determine 
whether they directly bind to each other using co-immunoprecipitation assays. Since 
both cathepsin B and DAPK-1 are reported to be involved in TNF- apoptotic 
pathways and TNF- have been shown to promote the degradation of DAPK-176, 121, 
166, 167, we reasoned that TNF- may mediate the degradation of DAPK-1 via 
enhancing its interaction with cathepsin B. Therefore, we set out to test whether 
TNFR-1 transfection altered the stability of the DAPK-1-cathepsin B immune 
complex. Because cathepsin B is a 29KDa protein, which is in size very close to the 
light chain in the IP reactions observed in western blot, we examined the expression 
of transfected TNFR-1 and its effect on endogeous cathepsin B in direct lysate first 
(Figure 3.6A) and it is clear that overexpressed TNFR-1 does not enhance the 
exrpression of endogenous cathepsin B. We then carried on to do 
immunoprecipitation and found that TNFR-1 transfection relative to vector control 
increased the co-precipitation of endogenous DAPK-1 with cathepsin B in lysates 
from three cell lines (Fig 3.6, B–D, lane 4 versus lane 3). Surprisingly, there was no 
detectable decrease in the total levels of DAPK-1 protein in direct lysates (Figure 3.6, 
B–D, lane 5 versus lane 1), suggesting that the increase in immune complex 
formation observed may not necessarily lead to a decrease in DAPK-1 protein level. 
Notably, the control IPs in Hela and A549 cells (lanes 2 in Figure 3B and Figure 3D) 
are  much stronger than that in HCT116 p53+/+ cells (lane 2 in Figure 3.6C). This 
may be due to differences in the expression level of endogenous DAPK-1 protein in 
these three cell lines (Figure 3.1). 
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We next set out to investigate the localization of endogenous DAPK-1 and cathepsin 
B. Because the commercial antibodies available can not detect endogenous DAPK-1 
by immunostaining, a subcellular fractionation kit was used23, 125. The fact that TNF-
 can induce the permeabilization of lysosomes and thus release cathepsin B into the 
cytosol168 led us to consider that TNFR-1 promoted the interaction between DAPK-1 
and cathepsin B by localizing both of them to the same cellular compartment. 
Therefore, we investigated the localization of DAPK-1 and cathepsin B by 
comparing the proportion of these two proteins in each fraction with or without 
TNFR-1 transfection (Figure 3.7A). As expected, after TNFR-1 transfection, the 
proportion of cathepsin B protein was elevated in the cytosolic fraction (Figure 3.7B) 
and mainly decreased in the “nuclear” fraction (Figure 3.7B). Moreover, the 
proportion of cytosolic DAPK-1 protein increased after TNFR-1 transfection (Figure 
3.7B) and the proportion of DAPK-1 in other fractions, especially the cytoskelaetal 
fraction, reduced after TNFR-1 transfection (Figure 3.7B). Interestingly, DAPK-1 
mobilities varied in different fractions (Figure 3.7A) and a duplex was observed in 
the “membrane and organelle” fractions (Figure 3.7A, lanes 2 and 6). This may be 
due the different buffers used in each fraction, or may reflect specific modifications 
of DAPK-1 such as phosphorylation in the “membrane and organelle” fraction since 
autophosphorylation of DAPK-1 is a common mechanism for the regulation of 
DAPK-1 activity as mentioned in Section 1.9. I then performed an 
immunoprecipitation from subcellular fractions 1–3 (Figure 3.7A) to evaluate the 
interaction of DAPK-1 and cathepsin B in these fractions (Figure 3.C). Fraction 4 
was not used because the protein precipitated in the buffer during the IP proceedure. 
A mixture of fractions 1, 2 and 3 were used in the control IP to make sure there was 
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no background detected in any of the fractions. It is clear that although the strongest 
DAPK-1 and cathepsin B complex is detected in the “nuclear” fraction (Figure 3.7C, 
lane 4), TNFR-1-mediated signalling elevated the DAPK-1/cathepsin B complex 
only in the cytosolic fraction since the proportion of DAPK-1/cathepsin B complex 
in this fraction increased from around 5% to around 40% (Figure 3.7D). Moreover, 
TNFR-1 mediated reduction of the DAPK-1-cathepsin B immune complex occurred 
in the “nuclear”fraction (Figure3.7D). Unexpectedly, the membrane and organelle 
fraction which has the highest levels of cathepsin B (Figure 3.7A, lanes 2 and 6) did 
not yield formation of a detectable immune complex between DAPK-1 and cathepsin 
B (Figure 3.7B, lane 6 and lane 3). These data suggest that DAPK-1 and cathepsin B 
are assembled into a very specific dynamic multiprotein complex. The TNFR-1 
mediated increase in DAPK-1/cathepsin B binding observed may be due to the 
relocalization of the proteins, since the lysis buffer used in the co-
immunoprecipitation assays is much more gentle compared to those in the last two 
fractions of the fractionation kit and TNFR-1 may actually function to drive some 
insoluble DAPK-1/cathepsin B complex into the cytosol.  
 
3.5 Role of DAPK-1/cathepsin B complex in TNF- 
signalling pathway 
In order to determine the functional role of the DAPK-1/cathepsin B complex in 
TNF- signalling pathway, I set out to define which region on DAPK-1 binds to 
cathespin B. First I examined whether TNFR-1 could promote the binding of 
transfected full-length DAPK-1 (1432 amino acids) with endogenous cathepsin B. 
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Similar to the previous results, TNFR-1 stimulated the formation of a DAPK-
1/cathepsin B complex as determined by immunoprecipitation (Figure 3.8A, lanes 3 
versus lane 2). Four DAPK-1 mutants with deletion of key functional domains were 
then created by site-directed mutagenesis (Figure 3.8B) When co-transfecting the 
DAPK-1 deletion mutants (Figure 3.9A, lanes 1–5) with TNFR-1 followed by 
immunoprecipitation with the cathepsin B antibody, only the longest DAPK-1 
mutant (residues 1–1313) bound to endogenous cathepsin B (Figure 3.9A, lane 10 
versus lanes 6–9). These data suggest that the region between 836 and 1313 is 
important for the binding of cathepsin B to DAPK-1.  
 
In addition the inverse IP experiment by performed, DAPK-1 was 
immunoprecipitated from cell extract and immunoblotting with cahtpesin B antibody. 
However, no complex could be observed. We considered it may be due to the 
masking of the binding site of DAPK-1 and cathepsin B by the antibody. Because the 
antibody was generated by using a fragment of DAPK-1 protein (694-947), which 
partially overlapps with the interaction domain that we mapped to amino acids (846-
1313).  We therefore generated another DAPK-1 deletion construct (residues 1-947) 
in order to map further the cathepsin B binding site. When co-transfecting the 
DAPK-1 deletion mutants (residues 1–835 and residues 1–947 with TNFR-1 
followed by immunoprecipitation with the cathepsin B antibody, only the DAPK-1 
mutant (residues 1–947) bound to endogenous cathepsin B (data not shown). This 
interaction was weak and the blot we obtained is not very clear.  However, the fact 
that the antibody immunogen overlapped with the domain we mapped convinced us 
that the 836-947 is the major component on DAPK-1 that cathepsin B interacts with.  
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The use of small peptide domains derived from full-length polypeptides to 
manipulate cell signalling is an emerging field called chemical genetics or peptide 
therapeutics169. Such mini-modules often reveal novel insights into signalling as a 
result of disrupting a specific protein interaction, and they can be expected to provide 
leads for drug design and development. To determine whether the minimal cathepsin 
B binding region of DAPK-1 acts in a gain-of-function or in a dominant negative 
fashion on TNFR-1-dependent apoptosis, the DAPK-1(836–947) miniprotein was 
transfected into cells to evaluate effects on cell signalling. A dose-dependent 
expression of DAPK-1(836–947) miniprotein can be observed after transfection 
(Figure 3.10A). Further, transfection of the cathepsin B expression vector results in 
reduction in levels of the DAPK-1(836–947) miniprotein (Figure 3.10B, lanes 4 
versus lanes 2), indicating an interaction between the two proteins in cells. An In 
vitro cleavage assay whereby I incubated purifed GST only with cathepsin B further 
confirmed that cathespin B downregulates GST-836-947 specifically via the 836-947 
minidomian rather than the GST-tag (Figure 3.10C).  Furthermore, the transfection 
of the vector encoding the DAPK-1(836–947) miniprotein resulted in a stimulation 
of TNFR-1-dependent PARP cleavage (Figure 3.11, lane 4 versus lanes 2 and 3). 
Interestingly, in this experiment the level of the unprocessed form of PARP is very 
similar despite the dramatic difference in the level of cleaved PARP (Figure 3.11). 
This may be due to the stimulation of the expression of unprocessed PARP by death 
signals like TNFR-1 via unknown mechanisms. Surprisingly, a significant decrease 
in endogenous DAPK-1 protein level was observed when combined with the 
transfection of TNFR-1 (Figure 3.11, lane 4 versus lanes 1–3), suggesting that 
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disruption of the endogenous DAPK-1/cathepsin B complex actually sensitises 
DAPK-1 to TNFR-1 mediated degradation. Therefore, although cathepsin B is 
capable of cleaving DAPK-1 and can form a stable complex with DAPK-1, TNFR-1 
mediated DAPK-1 degradation does not appear to be cathepsin B dependent. 
Moreover, endogenous cathepsin B may protect DAPK-1 from degradation in 
response to TNF- treatment. 
 
In order to determine whether changes in PARP cleavage correlated with changes in 
apoptosis, Annexin V staining and a TUNEL assay were used to quantify DAPK-1 
(836–947) miniprotein apoptotic function. The transfection of TNFR-1 resulted in 
increased apoptosis as defined by Annexin V staining (Figure 3.12A) that was further 
stimulated by the co-transfection of the DAPK-1(836–947) miniprotein (Figure 
3.12A). The transfection of TNFR-1 also resulted in apoptosis, as defined by TUNEL 
staining (Figure 3.12B), that was similarly stimulated by the co-transfection of 
DAPK-1(836–947) miniprotein (Figure 3.12B; quantitated in Figure 3.12C). This 
maximal level of apoptosis therefore correlated with the appearance of cleaved 
PARP and a reduction in endogenous DAPK-1 protein levels (Figure 3.11). 
 
Given that cathepsin B may have an inhibitory effect on TNF- signalled DAPK-1 
degradation, we used siRNA to cathepsin B to determine the actual role of the 
endogenous protein in regulating the rate of TNF--dependent apoptosis and DAPK-
1 degradation. Because the protein translation inhibitor cycloheximide can block NF-
B activity and greatly enhances the apoptotic effect of TNF-170 and it has been 
shown that TNF- and CHX combinatonal treatment degrades DAPK-1 much better 
 87
than TNF- alone62, 151, the cells were treated with TNF- plus CHX and the levels 
of apoptosis were evaluated by monitoring PARP cleavage (Figure 3.13A, lane 2 
versus lane 1). Treatment of cells with siRNA to cathepsin B led to depletion of 
cathepsin B protein (Figure 3.13A, lanes 5 and 6 versus lanes 2 and lanes 1) and a 
concomitant stimulation of PARP cleavage (Figure 3.13A, lane 6 versus lane 2). 
These data suggest that cathepsin B is a negative regulator of TNF-dependent 
apoptosis. Further, consistent with previous work, TNF- and CHX combinational 
treatment was able to degrade DAPK-1 better than TNF- or CHX alone, although 
TNF- treatment is enough to stimulate apoptosis (Figure 3.13B). In fact, DAPK-1 
levels increased slightly after TNF- or CHX treatment alone, suggesting a strong 
rather than subtle cell death signal may be necessary for the degradation of DAPK-1  
or the proteins involved in the inhibition of TNF- induced apoptosis such as Bcl-2 
are required to maintain DAPK-1 level upon TNF- stimulation. Moreover, the 
TNF-/CHX induced decrease was enhanced in combination with cathepsin B 
siRNA treatment (Figure 3.13B). These data support the idea that cathepsin B 
negatively regulates TNF- mediated DAPK-1 degradation and both cathepsin B and 
DAPK-1 might function as negative regulators of TNF--dependent apoptosis. In 
agreement, DAPK-1 protein depletion in response to TNF-treatment coincides 
with the appearance of PARP cleavage (Figure 3.13A, lane 6 versus lane 2). Further, 
attenuation of DAPK-1 expression failed to block the potent PARP cleavage 
observed in response to TNF- and CHX combined treatment (Figure 3.13C, lane 8 
versus lane 4) and actually increased PARP cleavage slightly in combination with 
TNF- treatment (Figure 3.13C, lane 6 vs lane2). This suggests that DAPK-1 
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negatively regulates TNF--mediated cell death and is consistent with a previous 
report showing that although DAPK-1 mediates interferon--dependent apoptosis, 
DAPK-1 protein depletion using morpholino technologies sensitizes cells to TNF--
dependent apoptosis18. 
 
Taken together, these data suggest that although cathepsin B is capable of cleaving 
DAPK-1, the physiological role of cathepsin B is to protect DAPK-1 from 
degradation. The activity of proteases can vary depending on the pH of the 
environment171, therefore it is possible that the DAPK-1/cathepsin B complex is 
formed in vivo, but the protease activity of cathepsin B is inhibited and the cleavage 
may actually occur during cell lysis. Therefore, lysis buffer was supplemented with 
MG132 or cathepsin B inhibitor to investigate whether the cleavage of DAPK-1 was 
blocked (Figure 3.14). Indeed inhibitors in the lysis buffer blocked the cleavage of 
endogenous DAPK-1, which confirmed that the majority of the cleavage occurred in 
vitro (Figure 3.14). 
 
3.6 Conclusion 
My study shows that DAPK-1 protein levels can be controlled post-translationally. 
While cathepsin B can interact with and cleave DAPK-1 protein during cell lysis in 
vitro (Figure 3.4, 3.5, 3.14), it appears the function of cathepsin B in cells is to 
protect DAPK-1 from TNFR-1 induced degradation since TNF- and CHX 
combinational treatment degrades DAPK-1 better in the absence of cathepsin B 
(Figure 3.13). It is not clear whether cathepsin B protects DAPK-1 simply by binding 
to it or through alternative pathways that requires its protease activity. The fact that 
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the DAPK-1 miniprotein GST-836-947 can be depleted by cathepsin B (Figure 3.10) 
and promote TNFR-1 induced DAPK-1 degradation suggestes that interaction 
between DAPK-1 and cathepsin B may be the key for this protection. An IP 
experiment has been performed to examine the interaction between GST-836-947 
and cathepsin B, but no stable complex could be observed (data not shown). This 
suggested that cathepsin B may not mediate the depletion of GST-836-947 via direct 
cleavage, but thorugh other unidentified degradation components such as the 
lysosome. Of note, it cannot be ruled out that the activity of cathepsin B still plays a 
role in this protection. Further experiments using cathepsin B inhibitor together with 
TNFR-1 may help to investigate this aspect more deeply.  
 
The siRNA experiment (Figure 3.13C) and other published work62, 151 suggest that 
DAPK-1 acts as a survival factor in the TNF- signalling pathway. Cathepsin B 
functions to protect DAPK-1 from TNFR-1 induced degradation. Considering that 
the expression of the ubiquitin E3 ligase DIP-1 for DAPK-1 promotes TNF--
induced apoptosis62, there may be a link between the ubiquitination of DAPK-1, its 
interaction with cathepsin B, and TNF- apoptotic responses.  
 
DAPK-1 is known to bind to early responsive components in the TNF- pathway, 
including TNFR-1 and FADD after brain seizures, although the physiological 
functions of these interactions are still unclear76, 166. Morpholino depletion of DAPK-
1 protein sensitizes cells to TNF--induced apoptosis, whereas a depletion of DAPK-
1 protein attenuates interferon--induced apoptosis (Figure 3.15A)18. These data 
indicate that DAPK-1 can exhibit prosurvival as well as proapoptotic signalling 
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properties. The discovery here of a TNFR-1-regulated interaction between cathepsin 
B and DAPK-1 raises the question of whether this complex would be prosurvival or 
proapoptotic. The stimulation of TNFR-1-induced apoptosis by either DAPK-1 or 
cathepsin B depletion using siRNA (Figure 3.13) suggests that this complex could be 
regulating the rate of TNF--dependent apoptosis by virtue of attenuating the 
apoptotic program. Using the cathepsin B binding domain of DAPK-1 as a tool to 
further test the mechanism of TNF--apoptotic signaling, we show that the DAPK-
(836–947) miniprotein can function in a dominant negative manner, resulting in a 
stimulation of DAPK-1 protein degradation and an increase in TNF--dependent 
apoptosis (Figure 3.15B). These data provide a genetic tool with which to dissect the 
mechanism of how DAPK-1 links to TNF- signalling in the future.  
 
The fractionation studies have demonstrated that there are distinct pools of DAPK-1 
that may have distinct functions (Figure 3.7A). These pools of DAPK-1 presumably 
will have distinct functions, possibly responding to ERK or other cytoskeleton-
responsive signalling pathways or regulate the autophagy pathways, Moreover, the 
duplex in the “membrane and organelle” fraction may be the caused by the 
autophosphorylation of DAPK-1. It will be interesting to test the activity of DAPK-1 
in each fraction to further investigate this observation.  
 
In addition to cathepsin B, several other proteases, such as cathepsin D and cathepsin 
L, are reported to be involved in TNF--induced apoptotic pathways100, 172, 173. 
Further, cathepsin D also mediates the interferon--triggered programmed cell death 
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like DAPK-18, 173. It will be interesting to investigate whether DAPK-1 has any 
connections with these cathepsin family members.  
 
DAPK-1 has been reported to bind to distinct proteins, such as ERK77, RSK155, and 
myosin light chain174. Our studies indicate that cathepsin B is a new member of this 
growing family of DAPK-1 binding partners with a novel binding domain localized 
in the C-terminal domain of DAPK-1 between the ankyrin repeats and the death 
domain. Given the ability of TNF--dependent pathways to induce apoptosis175, 176, 
studying how this DAPK-1/cathepsin B complex integrates with MEK-ERK-DAPK-
1131, RSK-DAPK-1, and DAPK-1-p53 signalling axes will shed light on signal 

















 Figure 3.1 DAPK-1 protein and mRNA quantification in cycling cells. Six different tumour cells, 
as indicated, were harvested, and each cell sample was split into two halves. Half was used for mRNA 
level test using one-step SYBR green real time PCR (top); the other was lysed in UREA buffer and 
used for DAPK-1 protein level quantification using immunoblotting. The relative mRNA level is 
depicted as a ratio of DAPK-1/actin. The non-specific control band was used as loading control. This 

















Figure 3.2 DAPK-1 protein and mRNA quantification upon viral stress. (A) The pIpC response 
of the p53 pathway. HCT116 p53+/+ cells were treated with and without pIpC for 6h (lanes 1 versus 
lanes 2), and the endogenous protein was extracted in UREA buffer and the expressions (as indicated; 
p53, DAPK-1, DAPK-2, DAPK-3, IRF-1, and loading control) were detected using the respective 
antibodies. Same non-specific band as in Figure 3.1 was used as control. This experiment has 
been performed more than 3 times. (B) DAPK-1 protein and mRNA quantification in stress 
responses. HCT116 p53+/+ and p53-/- cells were treated with pIpC for 6 h under normal culture or 
serum-starved conditions. Each cell sample was split into two halves. One was used for mRNA level 
quantification using real time PCR (top) and the other for DAPK-1 protein quantification using UREA 
lyssis and immunoblotting (bottom). The relative change in mRNA level is depicted as a ratio of 
DAPK-1/actin. The non-specific band as shown in Figure 3.1 was used as control. This experiment 


















Figure 3.3 DAPK-1 has a higher stability. (A) The stability of DAPK-1 protein in Hela cells was 
determined by CHX treatment for 1 h, 2 h, 3 h, 4 h, and 6 h and the protein expression in (A) was 
quantified in (B). DAPK-1 was extracted in UREA buffer and detected using a DAPK-1-specific 
antibody. The non-specific band as shown in Figure 3.1 was used as control. This experiment 


















Figure 3.4 Blockage of the cleavage bands of DAPK-1. (A) Endogenous DAPK-1 protein 
cleavage in MG132-treated cells. The effect of MG132 on endogenous DAPK-1 protein levels was 
analyzed in A549 cells treated with and without MG132 for 6 h before harvesting (lanes 1 versus 
lanes 2). DAPK-1 protein was extracted in UREA buffer and immunoblotted and the MG132-
dependent cleavage changes are depicted using. (B) The effect of a cathepsin B inhibitor on DAPK-
1 protein cleavage. A549 cells were treated with MG132 (lane 2) or a cathepsin B inhibitor 
(benzyloxycarbonyl-FA-fluoromethyl ketone) (lane 3) for 4 h before harvesting. The endogenous 
DAPK-1 was extracted in UREA buffer and detected by immunoblotting. Both experiments have been 


























Figure 3.5 In vitro cleavage of DAPK-1 by cathepsin B. 35S-labeled HA-DAPK-1 (2 g) was 
incubated with purified cathepsin B (0.1 units) in a 15l reaction volume for the indicated time points. 
The reaction was stopped with SDS-containing sample buffer, and protein was separated using SDS-
PAGE. The cleavage bands of DAPK-1 are depicted using arrows as I, II and III. (Radioacive HA-
DAPK-1 made by Dr. Jennifer Fraser) This experiment has been performed twice.  
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Figure 3.6 TNFR-1 enhances the complex formation between DAPK-1 and cathepsin B. (A) Hela 
cells were transfected with PCDNA3 (-) or vectors encoding TNFR-1 for 18h before harvesting. 
The lysates were extracted in NP40 buffer and then subjected to immunoblotting. The 
expression of TNFR-1 and cathepsin B was detected by respective antibodies. -actin was used 
as the loading control. This experiment has been observed more than 3 times. (B) Hela; (C) 
HCT116 p53+/+; (D) A549 cells were transfected with PCDNA3 (-) or vectors encoding TNFR-1 for 
18 h before harvesting. The lysates were extracted in NP40 buffer and then subjected to 
immunoprecipitation with a cathepsin B antibody and then probed with anti-DAPK-1 antibody. 
Mouse secondary antibody was used in the control immunoprecipitation. Lane 1, direct lysate with 
vector only transfection; lane 2, control immunoprecipitation; lane 3 and 4, immunoprecipitation in 
vector only or TNFR-1-transfected cells; lane 5, direct lysate with TNFR-1 transfection). In (B), a no 
lysate control (lane NL) immunoprecipitation was also performed to check the background of the 
antibody.  Cathepsin B IP for endogeous DAPK-1 experiments have been performed more than 3 tims.  
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Figure 3.7 TNFR-1 switches the localization of the DAPK-1/cathepsin B complex. (A) TNFR-1 
induces a DAPK-1 and cathepsin B mobilization to the cytosolic fraction. Hela cells were 
transfected with PCNDA3 (-) or vectors encoding TNFR-1 for 18 h before harvesting. The subcellular 
fractionation was performed using the fractionation kit from Calibiochem. DAPK-1 and cathepsin B 
were detected with respective antibodies. Lanes 1–4, DAPK-1 and cathepsin B levels in fractions 1–4 
in vector-only transfectants; lanes 5–8, DAPK-1 and cathepsin B levels in fractions 1–4 in TNFR-1 
transfectants. The proportion of DAPK-1 and cathepsin B  in each fraction in (A) was quantified 
in (B). (C) TNFR-1 switches DAPK-1/cathepsin B complex to the cytosolic fraction. The lysates 
of each fraction from (A) were immunoprecipitated with cathepsin B antibody and then probed with 
DAPK-1 antibody. Lanes 2–4, cathepsin B bound DAPK-1 levels in fractions 1–3 in vector-only 
transfectants; lanes 5–7, cathepsin B bound DAPK-1 levels in fractions 1–3 in TNFR-1 transfectants. 
A mixture of fractions 1,2 and 3 in vector only transfectant and a non-specific anti-mouse secondary 
antibody were used in the control IP. The proportion of pulled-out DAPK-1 in each fraction in (C) 









Figure 3.8 Generation of HA-DAPK-1 mutants. (A) TNFR-1 increases the binding between 
transfected HA-DAPK-1 and endogenous cathepsin B. HCT116 p53+/+ cells were transfected with 
PCNDA3 (-) or vectors encoding HA-DAPK-1 for 36 h and TNFR-1 for 18 h prior to harvest. The 
lysates were extracted in NP40 buffer and then subjected to immunoprecipitation with a cathepsin B 
antibody, and then both direct lysates and eluates were probed with an anti-HA antibody to quantify 
DAPK-1 binding. The expression of cathepsin B was detected by a cathepsin B antibody. The non-
specific band was used as a loading control. This experiment has been performed more than 3 times. 























Figure 3.9 Mapping the binding region of cathepsin B on DAPK-1. (A) DAPK-1 C-terminal 
domain deletion prevents cathepsin B binding in cells. HCT116 p53+/+ cells were transfected with 
PCNDA3 (-) or the indicated HA-DAPK-1 expression vectors for 36 h. The TNFR-1-encoding vector 
was transfected 18 h post-transfection of HA-DAPK-1 mutants. The cell lysates were extracted in 
NP40 buffer and then immunoprecipitated with a cathepsin B antibody and then probed with HA 







Figure 3.10 Characterization of DAPK-1-(836-947) mutant. (A) Expression of DAPK-1-(836–947) 
in cells. HCT116 p53+/+ cells were transfected with PCDNA3 (-) or vectors encoding GST-DAPK-1-
(836–947) for 36 h before harvest. The lysates were extracted in NP40 buffer and the expression of 
GST-DAPK-1-(836–947) was detected by GST antibody. -Actin was used as a loading control. This 
experiment has been performed more than 3 times.  (B) Cathepsin B transfection depletes the 
DAPK-1-(836–947) miniprotein. HCT116p53+/+ cells were transfected with PCDNA3 (-) or vectors 
encoding GST-DAPK-1-(836–947) and cathepsin B-GFP for 36 h before harvest. The lysates were 
extracted in NP40 buffer and the expression of GST-DAPK-1-(836–947) was detected by GST 
antibody, and cathepsin B was detected by GFP antibody.-Actin was used as a loading control. This 
experiment has been performed more than 3 times.  (C) Purified GST (2 g) was incubated with 
purified cathepsin B (0.1 units) in a 15l reaction volume for 30 minutes. The reaction was stopped 
with SDS-containing sample buffer, and protein was separated using SDS-PAGE. Cathepsin B and 























Figure 3.11 DAPK-1-(836–947) miniprotein promotes TNFR-1-dependent DAPK-1 degradation 
in cells. Hela cells were transfected with PCNDA3 (-) or vectors encoding GST-DAPK-1-(836–947) 
and TNFR-1 for 24h before harvest. The lysates were extracted in NP40 buffer and the expression of 
endogenous DAPK-1 and PARP were detected by respective antibodies. GST-836-947 was detected 
by GST antibody and its detection was performed in a separate western blot experiment. The non-
specific band as shown in Figure 3.1 was used as control. This experiment has been performed 




Figure 3.12 DAPK-1-(836–947) miniprotein enhances TNFR-1-dependent apoptosis in cells  
(Performed by Dr. Craig Stevens). (A) Annexin V quantitation of apoptosis stimulated by 
DAPK-1-(836–947). HCT116 p53+/+ cells were transfected with the indicated expression vectors for 
24 h before harvest. The apoptotic cells were then detected using the TACS Annexin V-fluorescein 
isothiocyanate apoptosis detection kit. The percentages of the apoptotic cells are presented in bar 
graphs. (B) TUNEL assay for quantifying apoptosis stimulated by DAPK-1-(836–947). 
HCT116p53+/+cells were transfected with the indicated expression vectors for 24h before staining. 
Apoptotic cells were labelled using an Apoptag Plus fluorescein in situ apoptosis detection kit S7111 
(Chemicon International). (C) The result of the TUNEL assay was analyzed by Image J, and the 
percentages of apoptotic versus total cells are presented in bar graphs. These experiments have 
been performed twice.  
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Figure 3.13 Roles of endogenous DAPK-1 and cathepsin B in TNF- induced apoptosis. (A) 
Effects on TNF- induced DAPK-1 degradation and PARP cleavage after cathepsin B protein 
reduction using siRNA. siRNA knockdown of cathepsin B was performed in Hela cells in 
combination with the TNF- and CHX treatments. DAPK-1, cathepsin B, and PARP were extracted 
in NP40 buffer and detected with the respective antibodies, as indicated. The non-specific band as 
shown in Figure 3.1 was used as control.  The expression of DAPK-1 protein in (A) was 
quantified in (B). (C) Effects on TNF- induced PARP cleavage after DAPK-1 protein reduction 
using siRNA.  siRNA knock-down of DAPK-1 was performed in Hela cells in combination with the 
TNF- and CHX treatments. DAPK-1 and PARP were extracted in NP40 buffer and detected with the 
respective antibodies, as indicated. The non-specific band as shown in Figure 3.1 was used as 























Figure 3.14 DAPK-1 cleavage can be blocked in vitro by cathepsin B inhibitor and MG132. 
10M MG132 or 10M cathepsin B inhibitor was added to the UREA lysis buffers before lysing Hela 
cells. The endogenous DAPK-1 and its cleavage bands were detected by DAPK-1 antibody. This 












Figure 3.15 Models for DAPK-1/cathepsin B complex in apoptosis pathways. (A) A model 
highlighting the two distinct pathways involving DAPK-1: a DAPK-1 survival function 
antagonizing TNF-dependent apoptosis and a DAPK-1 proapoptotic function in interferon-
dependent apoptosis. (B) A model highlighting the mechanism of DAPK-1 dependent 
attenuation of TNF- dependent apoptosis. Although cathepsin B has been reported to stimulate 
TNF--mediated apoptosis 99, 100, this current study shows that the depletion of either cathepsin B or 
DAPK-1 using siRNA can stimulate TNF--mediated PARP cleavage, suggesting the binding of 
DAPK-1 to cathepsin B attenuates TNF--mediated apoptosis. The induction of a DAPK-1/cathepsin 
B complex in the cytosol by TNF- signalling suggests that it may be the complex itself that has such 
prosurvival activity. Moreover, the ability of the DAPK-1 binding region for cathepsin B (miniprotein 
amino acids 836–947) to degrade endogenous DAPK-1, thus stimulating apoptosis, further suggests 
that it is this dimeric complex that can counter rates of TNF--mediated apoptosis. We propose that 
the DAPK-1 domain from amino acids 836–947 can interact with an “anchoring” factor (like 
cathepsin B) that normally keeps DAPK-1 in a stable state with a very slow turnover (Figure 3.3). 
This region is required to maintain the DAPK-1/cathepsin B complex, and the DAPK-1 miniprotein 
(amino acids 836–947) can bind to this endogenous anchor (possibly cathepsin B), releasing cathepsin 
B from DAPK-1 and　 resulting in TNF-dependent DAPK-1 protein degradation and enhanced 
apoptosis.  
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Chapter Four Identification of an alternative 
transcript from DAPK-1 locus 
4.1 Introduction 
DAPK-1 is relatively large for a protein kinase, and its independent functional 
domains are involved in various regulatory activities. The DAPK-1 kinase domain is 
required to mediate cytoskeleton remodeling by phosphorylating MLC 223, inhibiting 
cell migration150 and inducing membrane blebbing125. Furthermore, MAP1B  
interaction with the kinase domain of DAPK-1 stimulates membrane blebbing and 
autophagy25. The roles of its other functional domains in its regulatory effects are 
being characterized. For example, the death domain of DAPK-1 forms a docking site 
for its interaction with ERK, and is thus required for DAPK-1’s proapoptotic effect 
in response to the MEK⁄ERK signaling pathway77. Moreover, a germline mutation in 
the death domain of DAPK-1 has been found to reduce intrinsic oligomerization of 
the death domain, disrupt the binding of ERK, and thus prevent MEK⁄ ERK-induced 
apoptosis131. The death domain of DAPK-1 also promotes its interaction with the 
netrin-1 receptor UNC5H2, whose proapoptotic effect when unbound to netrin-1 is 
partially attenuated in the absence of DAPK-181. The ankyrin-repeat region of 
DAPK-1 is required for its proper localization to the actin stress fibers23 and for 
stable binding with DAPK-1’s ubiquitin E3 ligase DIP-1 62. Recently, it was shown 
that the LAR interacts with the ankyrin-repeat region of DAPK-1 and 
dephosphorylates DAPK-1 at pY491 ⁄ 492 to stimulate its proapoptotic and 
antimigration activities79. There are many regions ⁄ minidomains on DAPK-1 without 
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an ascribed function, and it is likely that further biochemical characterization will 
result in a greater understanding of the DAPK-1 gene product in autophagic and 
apoptotic cell signaling.  
 
In this part of my project, I identified an mRNA product of the DAPK-1 locus that 
encodes a small miniprotein (which I have named s-DAPK-1), that shares some 
domains with full-length DAPK-1: part of the ankyrin-repeat region, through to part 
of the cytoskeleton binding domain, but also includes with a unique tail extension of 
42 amino acids that is not present in full-length DAPK-1. The functions of s-DAPK-
1 compared to full-length DAPK-1 will be investigated. Furthermore, the roles of the 
unique tail of s-DAPK-1 in the regulation of its activity and stability will be 
investigated.   
 
4.2 Identification of s-DAPK-1 
Ankyrin repeats are versatile protein–protein interaction motifs178, thus proteins that 
contain ankyrin repeats have the potential to cross-talk with the DAPK-1 pathway. 
Therefore, we evaluated the homology of the ankyrin-repeat region of DAPK-1 with 
other genes in the human genome using the NCBI nucleotide blast tool. One Homo 
sapiens cDNA was identified: FLJ45958 fis, clone PLACE7011559, from the NEDO 
human cDNA sequencing project. The start of this expression clone matches intron 
13–14 of the DAPK-1 gene and stops on intron 20–21 (Figure 4.1A). The start codon, 
ATG, of this expression clone is located on the 10–12th base pairs of exon 15 within 
the DAPK-1 gene, which makes the translation of this clone in-frame with that of 
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DAPK-1 mRNA. After the start codon, this expression clone shares the same 
sequence as DAPK-1 mRNA through the end of exon 20, as indicated in Figure 4.1B, 
and its stop codon, TAG, is located on the 124–126th base pairs of intron 20–21 
(Figure 4.1A). Thus, the first 295 amino acids of this 337 amino acid protein are 
identical to the region of the DAPK-1 protein from residues 447–743, whereas the 
last 42 amino acids are unique for this product (Figure 4.1B). These data suggest that 
this product is highly similar to and may be a splice variant of DAPK-1. Because of 
its smaller size as compared to full-length DAPK-1, we have named it short-DAPK-1 
(s-DAPK-1).  
 
The transcription of s-DAPK-1 was demonstrated further by RT-PCR using the 
Stratagene QPCR Human Reference Total RNA and the primers located on both 
ends of the coding region of s-DAPK-1 mRNA (Figure 4.2A). In order to determine 
the expression of s-DAPK-1, we compared its mRNA expression with that of DAPK-
1 in three widely used tumour cell lines, and we saw a general correlation between 
full-length DAPK-1 and s-DAPK-1 mRNA levels (Figure 4.2B).  
 
4.3 Cleavage of s-DAPK-1 on its tail region 
To begin functional studies of s-DAPK-1, the s-DAPK-1 cDNA was reverse 
transcribed from the Stratagene QPCR Human Reference Total RNA and cloned into 
a Flag–Myc vector (Figure 4.3A), which contains an N-terminal Flag tag and a C-
terminal Myc tag, and this was followed by expression in HCT116 p53+⁄+ cells. Two 
major transfected bands were observed: a 44 kDa upper band, and a 40 kDa lower 
 110
band (Figure 4.3B). In order to determine which band corresponded to s-DAPK-1, 
the C-terminal Myc tag was deleted (Figure 4.3A). Upon transfection, the same 
lower protein band was observed in the Flag–s-DAPK-1- and the Flag–s-DAPK-1-
Myc-transfected cells, whereas the upper band in the Flag–s-DAPK-1 transfection 
lane was slightly smaller (Fig. 4.3C, lane 2 versus lane 1). This suggests that the 
depletion of the Myc tag only changes the size of the upper band, and that therefore 
the upper band represents the ‘full-length’ s-DAPK-1. 
 
Since the upper band is full-length s-DAPK-1, the appearance of the 40 kDa lower 
band in both Flag-s-DAPK-1 and Flag-s-DAPK-1-Myc transfected cells suggests a 
cleavage on s-DAPK-1. This is further suggested by the in vitro cleavage assay, in 
which the purified GST–s-DAPK-1 was incubated with HCT116 p53+⁄+ cell lysates. 
With increasing amount of cell lysates, GST–s-DAPK-1 was cleaved in vitro at a 
faster rate than GST alone (Figure 4.4), supporting the existence of a protease that 
cleaves s-DAPK-1 protein in vivo. The reason why the cleavage band was not 
observed in this assay may be the rapid degradation of the purified protein from the 
cell lysate. When subjected to a longer exposure, the blot showed multiple bands 
below GST–s-DAPK-1, which may mask the actual cleavage band. 
 
Two s-DAPK-1 deletion mutants, Flag-AO (Ankyrin repeat Only) and Flag-TD (Tail 
Deletion) were created (Figure 4.3A) to further investigate why the lower molecular 
mass protein was observed. Upon transfection, the Flag-TD vector produces only one 
major band of lower molecular mass (Figure 4.5, lane 3), which is similar to the 40 
kDa lower band produced from the full-length s-DAPK-1 (Figure 4.5, lane 4 versus 
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lane 3). This suggests that the lower band might be a cleavage product of the full-
length s-DAPK-1, and that the cleavage signal is within the C-terminal tail extension. 
The higher molecular mass protein band (~54 kDa) observed in Flag-s-DAPK-1 
transfected cells (Figure 4.5, lane 4) might result from a covalent adduct resulting 
from ubiquitin-like modification; nevertheless, this apparent adduct is dependent 
upon the integrity of the C-terminal tail extension. 
 
Having identified that the cleavage occurs within the tail region, I next investigated 
which sites within the tail are the critical targets for cleavage. Because the 
transfected Flag-TD vector is similar to the in vivo cleaved form of Flag–s-DAPK-1 
in size, five tail mutants (TMs) of s-DAPK-1 were created to screen the first 10 
amino acids on the tail for proteolytic susceptibility (Figure 4.6A). Upon transfection, 
only Flag-TM1 exhibited a loss of proteolytic band, and Flag-TM2 showed a 
weakened cleavage band (Figure 4.6B). These data suggest that the first two amino 
acids of the tail are critical for proteolytic susceptibility, and that the third and fourth 
amino acids are involved in the regulation of this cleavage. This also further fine-
maps the site of cleavage, and indicates that the tail deletion Flag-TD may be used as 
a mimic of the in vivo processed form of full-length s-DAPK-1. Flag-TM3 
surprisingly produced a specific shift in size under denaturing conditions, suggesting 
that the modification of the fifth amino acid on the tail may alter its secondary 
structure in denaturing polyacryl-amide gels or might yield an undefined covalent 
adduct (Figure 4.6B, lane 4).  
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As described in Chapter Three, cathepsin B is capable of cleaving DAPK-1. 
Although the binding site of cathepsin B does not lie on the ankyrin repeats region of 
DAPK-1, it is still possible that cathepsin B can interact with this region on DAPK-1. 
Therefore, I set out to test whether the cleavage of the tail region of s-DAPK-1 is 
induced by cathepsin B by treating the Flag-s-DAPK-1 transfected cells with 
cathepsin B inhibitor. No difference of the s-DAPK-1 cleavage pattern was observed 
between the treated (Figure 4.7, lane 3) and the untreated cells (Figure 4.7, lane 2), 
suggesting cathepsin B is not responsible for the observed cleavage of s-DAPK-1.  
 
4.4 Functions of s-DAPK-1 
The proapoptotic effect in response to MEK⁄ERK signaling and the membrane-
blebbing-promoting effect upon transfection are two readily measurable functions of 
DAPK-177, 125, 131. Therefore, we set out to define the role of s-DAPK-1 in these two 
pathways. Unlike DAPK-1, overexpression of s-DAPK-1 does not induce PARP 
cleavage in response to the MEK⁄ERK signal input (Figure 4.8, lane 6 versus lane 5). 
Interestingly, when co-transfected with ERK, the expression level of DAPK-1 
reduces dramatically, while that of s-DAPK-1 remains the same, suggesting that 
ERK may regulate the degradation of DAPK-1 via its interaction with the death 
domain of DAPK-1. Further research will be needed to investigate this ERK-indued 
reduction of DAPK-1 in the future. We next compared the effect s-DAPK-1 in 
membrane blebbing with full-length DAPK-1. The transfection of Flag–s-DAPK-1 
was able to cause significant membrane blebbing, however the effect was weaker 
than observed with full-length DAPK-1 (Figure 4.9).  
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4.5 Regulation of s-DAPK-1 by its tail region 
Since s-DAPK-1 exhibits biological activity in the membrane-blebbing assay, I 
evaluated the activity of the mutant with the tail deletion (Flag-TD) and the protease-
resistant substitution (Flag-TM1). When compared to full-length s-DAPK-1, Flag-
TM1 showed a reduced membrane-blebbing effect (Figure 4.10), whereas Flag-TD 
was almost as active as full-length DAPK-1 (Figure 4.10). These data indicate that 
the ‘tail’ of s-DAPK-1 has a negative regulatory function with regard to s-DAPK-1 
activity, and that its removal serves to enhance the membrane-blebbing effect of s-
DAPK-1. 
 
To determine the mechanism that underlies the effect of the tail on the membrane-
blebbing-promoting ability of s-DAPK-1, the localization and half-lives of the full-
length s-DAPK-1, Flag-TD and Flag-TM1 were examined. As compared to DAPK-1, 
s-DAPK-1 shows more specific localization in the cytoplasm (Figure 4.11). TD 
predominantly localizes around the nucleus, and TM1 spreads throughout the cytosol 
and tends to form some ‘aggregating bodies’ (Figure 4.11). It is still not clear what 
these bodies are. Co-staining of TM1 with other speicifc antibodies for distinct 
structural bodies such as lysosome may help to clarify this in the future. Moreover, 
the stability of TD is much higher than those of s-DAPK-1 and Flag-TM1 (Figure 
4.12 A–E), suggesting that the increased membrane-blebbing function of TD may be 




DAPK-1 is a stress-regulated kinase whose downstream functions are linked to a 
variety of diverse signalling pathways, including ERK kinase activation, autophagic 
signalling, and oncogene-mediated p53 transcriptional responses. DAPK-1 is also 
regulated by TNF- signalling, RSK, and L, which alter the specific activity of the 
kinase as a prosurvival or proapoptotic factor. Although the DAPK-1 protein is now 
known to be regulated post-translationally, the gene is also subject to methylation, 
which has the potential to reduce the specific activity of DAPK-143. In this work, I 
have identified another function of the DAPK-1 locus: it can express a message 
whose product possesses part of DAPK-1’s ankyrin-repeat region, P-loop, and 
cytoskeletal binding domain, and a unique tail of 42 amino acids encoded by intron 
20–21 of the DAPK-1 gene. In our examination of DAPK-1 and s-DAPK-1 
expression using real-time PCR, we found a significant correlation in their 
expression, whether using cancer cell lines or normal human tissues, suggesting that 
mRNA from the locus is coordinately produced. Future work will be required to 
understand the regulation of the translation of these mRNAs and whether stress-
regulated signaling pathways regulate these two proteins differently in cell growth 
control. 
 
Despite the many functions attributed to DAPK-1, the two standard cellular assays 
for defining its function include proapoptotic pathways and membrane blebbing. 
Therefore, we have examined the ability of the s-DAPK-1 protein to play a role in 
these two processes. We found that although s-DAPK-1 cannot induce apoptosis in 
response to the activated MEK⁄ERK signal like DAPK-1, it can mimic DAPK-1 and 
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induce membrane blebbing. A function was also attributed to the unique tail of s-
DAPK-1: it can regulate the localization and stability of the protein and can be 
subjected to proteolytic cleavage in cells. Thus proteolytic cleavage of the tail 
relocalizes s-DAPK-1 to increase its stability and membrane blebbing activity 
(Figure 4.12). 
 
DAPK-1 has been shown to induce membrane blebbing and promote the formation 
of actin stress fibers and disassembly of focal adhesions22. These biological events 
can occur in cooperation with MAP1B25, for which the ability of DAPK-1 to 
phosphorylate MLC 223 and tropomyosin-173 are considered to be important. 
However, it was also shown that the ankyrin-repeat region deletion mutant of DAPK-
1 mislocalized to focal contacts and lost its ability to induce morphological changes23, 
indicating a functional role of this region in DAPK-1’s activity. This might explain 
the membrane-blebbing-promoting effect of s-DAPK-1, as it shares a portion of the 
ankyrin-repeat region of DAPK-1. However, the functional significance of the s-
DAPK-1-induced membrane blebs is not clear, as s-DAPK-1 cannot induce MEK⁄ 
ERK-stimulated apoptotic signals (Figure 4.8). A recent study has provided a novel 
insight into membrane blebbing138; it was shown that membrane blebbing is due to 
the reassembly of the contractile cortex. Therefore, distinct from the alternative 
models showing that membrane blebbing is linked to autophagic or cell death 
pathways, membrane blebbing may also be part of a normal cell division processes 
such as cytokinesis. Considering that ankyrin B plays an important role in the 
membrane-blebbing process138, DAPK-1 and s-DAPK-1 may be able to interact with 
ankyrin B via their ankyrin repeats and thus promote membrane blebbing. Although 
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these data provide an explanation for the significance of the ankyrin-repeat region of 
DAPK-1 in inducing morphological changes, they do not necessarily indicate that 
DAPK-1- or s-DAPK-1-induced membrane blebbing is part of a normal cell division 
cycle. Considering that physiological membrane blebbing is a transient process138, it 
also remains possible that DAPK-1 and s-DAPK-1 arrest the cells at the blebbing 
stage and thus halt the cell division cycle. Therefore, the actual biological 




































Figure 4.1 Identification of a small transcript from the DAPK-1 locus. (A) A schematic map of s-
DAPK-1 mRNA in relation to the DAPK-1 gene structure. The mRNA of s-DAPK-1 starts in 
intron 13–14 of the DAPK-1 gene. Its coding region starts from the 10th base pair on exon 15 of the 
DAPK-1 gene, and shares the same splicing as full-length DAPK-1 through the rest of exons 15, 16, 
17, 18, 19 and 20. s-DAPK-1’s coding region stops at the 126th base pair of intron 20–21 of the 
DAPK-1 gene, and the 3’-UTR extends through the middle of intron 20–21. (B) Comparison of the 
protein sequences of DAPK-1 and s-DAPK-1. The first 295 amino acids of s-DAPK-1 are identical 
















Figure 4.2 Expression of s-DAPK-1 mRNA. (A) Identification of s-DAPK-1 mRNA. RT-PCR was 
performed using the Stratagene QPCR Human Reference Total RNA, and the products were subjected 
to electrophoresis and staining with ethidium bromide. (B) mRNA level test using SYBR Green 









Figure 4.3 Identification of a proteolytic cleavage of s-DAPK-1 protein. (A) A schematic 
diagram of the Flag–Myc vector with the s-DAPK-1 clone and its mutants created by site-
directed mutagenesis. The vector encoding the s-DAPK-1 with a 42 amino acid tail deletion is 
named Flag-TD. The vector encoding only the ankyrin repeats region of s-DAPK-1 is named Flag-AO. 
(B,C) Transfected s-DAPK-1 and its mutants identified a cleavage on s-DAPK-1. HCT116 p53+ ⁄ 
+ cells were transfected with empty Flag vector (EV) or the respective vectors, as indicated, for 24 h 
prior to harvesting. Expression of the ectopically expressed s-DAPK-1 and its mutants was detected 
using an antibody to Flag tag. The non-specific band in 4.3 (B) was used as the control. These 






















Figure 4.4 In vitro cleavage of purified GST–s-DAPK-1. Recombinant GST–s-DAPK-1 was 
purified from Bl21 cells and incubated at 30oC with increasing amounts of HCT116 p53 +⁄+ cell 
lysates (0, 1, 5, 10 and 20 L). The sample mixtures after in vitro cleavage were subjected to 


















Figure 4.5 Identification of the cleavage site of s-DAPK-1 within its tail. Transfected s-DAPK-1 
and its mutants identified a cleavage within its tail. HCT116 p53 +⁄+ cells were transfected with empty 
Flag vector (EV) or Flag-s-DAPK-1 and its mutants Flag-AO (Ankyrin repeat only) and Flag-TD 
(Tail deletion) for 24 h prior to harvesting. Expression of the ectopically expressed s-DAPK-1 and its 
mutants was detected using an antibody to Flag tag. The non-specific band as shown in 4.3 (B) was 









Figure 4.6 Identification of the critical sites for proteolytic cleavage of the C-terminal tail of s-
DAPK-1. (A) A schematic diagram of the tail mutants of s-DAPK-1 created by site-directed 
mutagenesis. (B) Expression of the tail mutants of s-DAPK-1. HCT116 p53 +⁄+ cells were 
transfected with empty Flag vector (EV) or the respective vectors, as indicated, for 24 h prior to 
harvesting. Expression of the s-DAPK-1 tail mutants was detected by immunoblotting. The non-
specific band as shown in 4.3 (B) was used as the control. This experiment has been performed 





















Figure 4.7 Cleavage of s-DAPK-1 is not inhibited by cathepsin B inhibitor. HCT116 p53 +/+  
cells were transfected with empty Flag vector (-) or the Flag-s-DAPK-1 vectors for 24h and treated 
with cathepsin B inhibitor for 6h prior to harvesting. The Flag-s-DAPK-1 protein was detected by 
immunoblotting. The non-specific band as shown in 4.3 (B) was used as the control. This experiment 

















Figure 4.8 s-DAPK-1 does not induce apoptosis in response to MEK ⁄ ERK signaling. HEK293 
cells were transfected with the PCDNA3 (EV) or the respective vectors, as indicated, for 24 h prior to 
harvesting. The unprocessed form and cleaved form of PARP were detected with a PARP-specific 





















Figure 4.9 s-DAPK-1 induces membrane blebbing. A375 cells were transfected with GFP in 
addition to the respective vectors as indicated, and evaluated for membrane blebbing in transfected 
cells as described previously125 . The top panel shows the normal (1) and the blebbing (2) morphology. 
The bar graph in the bottom panel summarizes the mean percentage of blebbing cells upon each 
transfection. Each experiment was repeated four times. This experiment has been performed more 






















Figure 4.10 The C-terminal tail of s-DAPK-1 regulates its membrane-blebbing function. A375 
cells were transfected with GFP in addition to the respective vectors as indicated (wt, TM1, and TD) 
and evaluated for membrane blebbing in transfected cells as described previously125. The bar graph 
summarizes the mean percentage of blebbing cells upon each transfection. Each experiment was 











Figure 4.11 The C-terminal tail of s-DAPK-1 regulates its localization. A375 cells were 
transfected with the respective vectors as indicated (GFP control, GFP-wt s-DAPK, GFP-TM1, GFP-
TD, and HA-DAPK-1). The localization of GFP and GFP-tagged proteins were detected using 
fluorescent microscopy. HA–DAPK-1 protein expression was detected using an antibody to HA tag. 















Figure 4.12 The C-terminal tail of s-DAPK-1 regulates its stability. (A–D) HCT116 p53 +⁄+ cells 
were transfected with empty Flag vector (-) or the respective vectors as indicated for 24 h, then treated 
with cycloheximide for the indicated times, prior to harvesting. Expression of the Flag-tagged proteins 
was evaluated by immunoblotting. The non-specific band as shown in 4.3 (B) was used as the control. 
Quantification of the level of Flag-s-DAPK-1, Flag-TD and Flag-TM1 in (D) is summarized in (E). 
These experiments have been performed more than 3 times.  
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Chapter Five s-DAPK-1 induces lysosome-dependent 
DAPK-1 destabilization 
5.1 Introduction 
In unstressed cells DAPK-1 is relatively stable 151. DAPK-1 stability can be regulated 
through the action of two ubiquitin E3 ligases, MIB1 and CHIP, which target DAPK-
1 for proteasomal degradation 64. It has been demonstrated previously that reduction 
of either MIB1 or CHIP can efficiently rescue the DAPK-1 degradation induced by 
the binding of Geldanamycin to Hsp9064, however there is no evidence that either of 
these E3s control the steady state levels of DAPK-1 protein, or are responsible for 
the DAPK-1 degradation in response to stresses such as TNF- or ceramide 62, 151. 
Therefore, it is possible that other ubiquitin E3s or alternative degradation pathways 
can regulate the degradation of DAPK-1 protein.    
 
As shown in Chapter Four, the splice variant of DAPK-1, s-DAPK-1, can mimic the 
membrane blebbing promoting ability of full-length DAPK-1, which is regulated by 
the tail region of s-DAPK-1. I next set out to investigate whether s-DAPK-1 can 
influence the activity or expression of full-length DAPK-1 when co-expressed with 
DAPK-1. In this chapter, I show that s-DAPK-1 is able to promote the degradation of 
full-length DAPK-1, which is dependent upon the ankyrin repeats region of s-
DAPK-1 and the kinase domain of DAPK-1. In addition, s-DAPK-1 does not target 
DAPK-1 for proteasomal degradation, although s-DAPK-1 itself is rapidly degraded 
by the proteasome. These data suggest that one function for s-DAPK-1 is to regulate 
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the steady-state levels of full-length DAPK-1 and implicates a proteasome-
independent degradation pathway for DAPK-1.  
 
5.2 s-DAPK-1 decreases DAPK-1 level 
The Ankyrin repeat is a common protein-protein interaction domain in a wide range 
of proteins178. As both s-DAPK-1 and DAPK-1 contain ankyrin repeats, I first set out 
to investigate whether they can interact with each other using immunoprecipitation. 
Although GFP-s-DAPK-1 was successfully immunoprecipitated by the GFP 
antibody, no co-immunoprecipitated HA-DAPK-1 was detected in s-DAPK-1 
immune complexes (Figure 5.1).  These data indicate that s-DAPK-1 and DAPK-1 
cannot form stable immune-complexes. However, a significant decrease in HA-
DAPK-1 protein expression was observed in direct lysates after GFP-s-DAPK-1 was 
co-transfected into cells (Figure 5.1, lane 4 vs lane 2),  suggesting that s-DAPK-1 can 
downregulate DAPK-1 protein levels. This is further confirmed by a titration 
experiment showing increasing amounts of GFP-s-DAPK-1 leads to a reduction of 
HA-DAPK-1 protein (Figure 5.2).  
 
5.3 Domains responsible for s-DAPK-1 mediated DAPK-1 
decrease 
Using deletion mutants of s-DAPK-1, I have demonstrated in Chapter Four that the 
tail region of s-DAPK-1 attenuates its ability to induce membrane blebbing, most 
likely due to the decreased stability of the full-length s-DAPK-1 compared to its tail-
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deleted form. Therefore, we next investigated which domain on s-DAPK-1 can 
influence its new function to downregulate DAPK-1 using the TD and AO mutants 
of s-DAPK-1 (Figure 4.3). Interestingly, although the ankyrin repeats region of s-
DAPK-1 does not mediate the interaction between DAPK-1 and s-DAPK-1, it is 
capable of inducing the decrease in DAPK-1 protein levels (Figure 5.3A). To further 
confirm this effect and find out whether the recombinant polypeptide tags influence 
this new function of s-DAPK-1, HA-DAPK-1 was co-transfected with s-DAPK-1 
and the same TD and AO mutants in Flag-tagged vectors, which resulted in a similar 
destabilization of HA-DAPK-1 protein (Figure 5.3B). These data suggest the ankyrin 
repeat region of s-DAPK-1 is critical for its ability to mediate the downregulation of 
DAPK-1 protein. Moreover, the TD mutant is more able to destabilize DAPK-1 
protein level compared to full-length s-DAPK-1, which is consistent with our 
previous finding that the tail possesses an inhibitory effect towards s-DAPK-1 
activity.  
 
Since the ankryin repeat region on s-DAPK-1 is identical to part of the ankyrin 
repeats region of DAPK-1, and is important for its ability to downregulate DAPK-1 
protein (Figure 5.3), it is of interest to see whether the ankyrin repeat region on 
DAPK-1 is also critical for its regulation by s-DAPK-1. Two deletion mutants of 
DAPK-1 HA-1-378 (containing the end of CaM binding region of DAPK-1) and 
HA-1-641 (containing the end of ankyrin repeat region of DAPK-1) (Figure 3.8B) 
were co-transfected with GFP-s-DAPK-1. Surprisingly, s-DAPK-1 not only 
decreases the level of the DAPK-1(1-641) mutant, but also that of the DAPK-1(1-
378) mutant (Figure 5.4). As this recombinant DAPK-1 deletion mutant 1-378 does 
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not contain the ankyrin repeat region, these data suggest that the determinant 
responsible for s-DAPK-1 induced downregulation of DAPK-1 lies within the 
DAPK-1 core kinase domain.  
  
5.4 s-DAPK-1 targets DAPK-1 for lysosome-dependent 
degradation 
In order to determine the mechanisms underlying this s-DAPK-1 mediated 
downregulation of DAPK-1 protein, we investigated the half-lives of DAPK-1 in the 
presence or absence of s-DAPK-1 using the translation inhibitor cycloheximide. As 
is shown, DAPK-1 by itself is still very stable after 4 hours of treatment with 
cycloheximide (Figure 5.5A), which is consistent with previous findings showing 
DAPK-1 is stable in Chapter Three. When s-DAPK-1 was co-transfected into cells 
with DAPK-1, the stability of DAPK-1 was reduced substantially after 4-hour 
treatment of cycloheximide (Figure 5.5B), suggesting s-DAPK-1 could downregulate 
DAPK-1 by stimulating its degradation. Interestingly, although s-DAPK-1 was 
depleted by cycloheximide after around 1h treatment (Figure 5.5B), DAPK-1 level 
continued to drop afterwards, which again suggests that s-DAPK-1 mediates the 
degradation of DAPK-1 protein via an indirect pathway rather than direct binding to 
it.   
 
As discussed in Chapter One, lysosomal and ubiquitin-proteasomal degradation 
pathways are the two pathways responsible for protein destruction inside cells and 
the latter usually applies to short half-life proteins50. Therefore, we set out to test 
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whether s-DAPK-1 promotes DAPK-1 degradation by targeting DAPK-1 towards the  
proteasome using the proteasome inhibitor MG132. MG132 greatly enhanced the 
level of s-DAPK-1 (Figure 5.6), which suggests s-DAPK-1 itself is degraded by 
proteasome, and is consistent with its rapid turnover (Figure 5.5B). However, 
MG132 didn’t rescue DAPK-1 from s-DAPK-1 mediated degradation (Figure 5.6), 
implicating an alternative proteasome-independent degradation pathway for DAPK-1 
by s-DAPK-1.  
 
Next I used the lysosome inhibitor chloroquine instead of MG132 in the same 
experiments to test whether this alternative degradation pathway for DAPK-1 is via 
lysosome. Chloroquine successfully rescues DAPK-1 from s-DAPK-1 induced 
degradation while has little effect on s-DAPK-1 (Figure 5.7, lane 5 vs lane 4). 
Interestingly, even in the absence of s-DAPK-1, chloroquine greatly enhanced the 
level of DAPK-1 (Figure 5.7, lane 3 vs lane 2), suggesting this lysosomal 
degradation pathway is important in regulating the steady state of DAPK-1.  
 
5.5 Conclusion 
An interesting observation we found is that the in vivo cleavage of the tail region of 
s-DAPK-1 is reduced substantially when s-DAPK-1 is cloned into GFP vectors and 
expressed in cells (Figure 5.3, lane 5 in (A) vs lane 5 in (B)). Previous reports have 
shown that protein tags are capable of changing the conformational structures of their 
fusion proteins179, 180. The inhibition of the proteolytic cleavage of the tail region of 
GFP-s-DAPK-1 in vivo may be due to the conformational changes brought by the 
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much bigger GFP tag compared to Flag tag, which masks the sites for cleavage on 
the tail and prevent the protease from binding.  Alternatively, GFP has been reported 
to have some toxic effects in some biological assays181 and therefore may change the 
signalling networks that control the s-DAPK proteolytic processing pathway.  
 
In this study, we have demonstrated that s-DAPK-1 protein can be turned over 
relatively rapidly (Figure 5.5B) and be degraded by a proteasome-dependent pathway  
(Figure 5.6), which is consistent with Chapter Four showing s-DAPK-1 is unstable. 
The DAPK-1 ubiquitin E3 ligase, MIB1, binds to the ankyrin repeats region of 
DAPK-1 composed of 265 amino acids62, the last 190 of which consist of the ankyrin 
repeats region of s-DAPK-1. Therefore, it remains possible that MIB1 might be the 
ubiquitin E3 ligase that targets s-DAPK-1 for proteasomal degradation. If so, s-
DAPK-1 may actually protect DAPK-1 from degradation when MIB1 become the 
main factor activated to degrade DAPK-1 under certain stresses. Such potential 
stresses implicated in MIB1 function are not yet defined.  
 
The ankyrin repeats region of s-DAPK-1 are sufficient to promote the degradation of 
DAPK-1 (Figure 5.3). Ankyrin repeat containing proteins are widely expressed in 
cells, and some of them are even contained within ubiquitin E3 ligases such as the 
HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1 
(HACE1)182. It is possible that s-DAPK-1 can crosstalk with some of these ankyrin 
repeat containing proteins and actually activate a general rather than a DAPK-1 
specific degradation pathway. Therefore, it will be interesting to investigate whether 
s-DAPK-1 can affect the stability of other proteins in the cell. Further, as a tumour 
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suppressor, the expression level of DAPK-1 is very important for growth suppression 
in some cancer types15. Under certain stresses such as that induced by TNF-, 
DAPK-1 actually acts as an anti-apoptotic factor and is targeted for degradation 151. 
Our study provides a new angle for studying the regulation of DAPK-1 protein 
degradation and suggests a potentially central role for s-DAPK-1 in DAPK-1 biology.   
 
Another ubiquitin E3 ligase, CHIP, binds to DAPK-1 via Heat Shock protein 90 
(Hsp90), which recognizes the kinase domain of DAPK-178. The fact that the kinase 
domain of DAPK-1 is responsible for s-DAPK-1 mediated DAPK-1 degradation 
(Figure 5.4) suggests s-DAPK-1 might function via a CHIP-dependent pathway. 
However, the proteasome inhibitor MG132 cannot rescue DAPK-1 from s-DAPK-1 
induced degradation (Figure 5.6), suggesting s-DAPK-1 doesn’t degrade DAPK-1 
through CHIP-proteasome pathway, and implicating the existence of an alternative 
proteasome independent degradation pathway for DAPK-1. Considering the 
relatively high stability of DAPK-1 protein 62, it is likely that there is a proteasomal-
independent and lysosomal-mediated degradation pathway regulating the steady state 
levels of DAPK-1 protein, which is confirmed by the observation that chloroquine 
stabilized DAPK-1 in the absence and presence of s-DAPK-1 (Figure 5.7).  
 
Interestingly, even in the absence of s-DAPK-1, MG132 doesn’t seem to greatly 
stabilize DAPK-1 protein (Figure 5.6, lane 3 vs lane 2). This is different from what is 
demonstrated in Chapter Three that MG132 can stabilize DAPK-1 protein and induce 
high molecular mass adducts in a denaturing polyacrylamide gel, which may be due 
to the difference of endogenous and exogenous DAPK-1 proteins used in each 
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experiment. Moreover, the effect of MG132 on DAPK-1 protein levels may vary in 
different tumour cell lines, for tumour cell lines could lose or gain degradation 
pathways because of the different mutations occurring in each cell line. 
 
In addition, it has been reported recently that inhibition of the proteasome 
degradation pathway leads to activation of autophagy183. Moreover, DAPK-1 was 
found to actively participate in the induction of autophagy, partially through binding 
to its interactive partner MAP1B25. Therefore, it is possible that MG132 activates an 
additional autophagy-lysosomal degradation pathway for the destruction of DAPK-1, 
which can engulf the ubiquitinated DAPK-1 created by the inhibition of proteasome. 
Thus, it still can not be ruled out that CHIP-proteasome degradation pathway is 
involved in s-DAPK-1 mediated DAPK-1 degradation and MG132 does stop some 
degradation pathways for DAPK-1. In order to better understand the degradation of 
DAPK-1, further experiments will be required to investigate the degradation 






























Figure 5.1 s-DAPK-1 doesn’t bind to DAPK-1, but decreases its level. A375 cells were transfected 
with PCDNA3 (-) or the respective vectors as indicated, for 24h, prior to harvesting. The lysates were 
subjected to immunoprecipitation with a GFP antibody and then probed with anti-HA and anti-GFP 
antibody. Expression of HA-DAPK-1 and GFP-s-DAPK-1 were evaluated by immunoblotting. The 
non-specific band as shown in Figure 3.8 (A) was used as the loading control. This experiment has 

























Figure 5.2 Titration of s-DAPK-1 with DAPK-1 overexpression. A375 cells were transfected with 
PCNDA3 (-) or 1g of HA-DAPK-1 vector together with increasing amount of GFP-s-DAPK-1 
vector (0, 1, 2, 3g in lanes 2-5 respectively) as indicated, for 24h, prior to harvesting. Expression of 
HA-DAPK-1 and GFP-s-DAPK-1 were evaluated by immunoblotting. The non-specific band as 
shown in Figure 3.8 (A) was used as the loading control. This experiment has been performed 















Figure 5.3 The ankyrin repeat region of s-DAPK-1 is sufficient to stimulate the decrease in 
DAPK-1 protein levels.  (A) s-DAPK-1(GFP-tagged) destabilizes DAPK-1. A375 cells were 
transfected with PCDNA3 (-) or the expression vector [GFP-tagged s-DAPK-1 and 
its mutants] for 24h, prior to harvesting. The lysates were subjected to 
immunoblotting using anti-HA and anti-GFP antibody.  The non-specific band as shown in 
Figure 3.8 (A) was used as the loading control. (B) s-DAPK-1(FLAG-tagged) destabilizes DAPK-1. 
A375 cells were transfected with PCDNA3 (-) or the expression vector [FLAG-
tagged s-DAPK-1 and its mutants] for 24h, prior to harvesting. The lysates were 
subjected to immunoblotting using anti-HA and anti-FLAG antibody. The non-specific 
band as shown in Figure 3.8 (A) was used as the loading control. These experiments have been 





















Figure 5.4 The kinase domain of DAPK-1 is the minimal determinant for s-DAPK-1 stimulated 
decrease in DAPK-1 protein levels. A375 cells were transfected with PCDNA3 (-) or HA-DAPK-1 
mutants and GFP-s-DAPK-1 expression vectors as indicated, for 24h, prior to harvesting. Expression 
of the HA-tagged proteins and GFP-s-DAPK-1 were evaluated by immunoblotting. The non-specific 
band as shown in Figure 3.8 (A) was used as the loading control. This experiment has been 



















Figure 5.5 s-DAPK-1 decreases DAPK-1 stability. (A, C) HEK293 cells were transfected with 
PCNDA3 (-) or expression vectors as indicated, for 24h, in combination with cycloheximide treatment 
for indicated time, prior to harvesting. Expression of HA-DAPK-1 and GFP-s-DAPK-1 were 
evaluated by immunoblotting. The non-specific band as shown in Figure 3.8 (A) was used as the 
loading control. Quantification of DAPK-1 levels in (A) and (C) is summarized in (B) and (D). These 
























Figure 5.6 s-DAPK-1 stimulated DAPK-1 degradation is proteasome independent. HEK293 cells 
were transfected with PCDNA3 (-) or the respective expression vectors as indicated, for 24h, in 
combination with MG132 (lanes 3 and 5) treatments for 6h, prior to harvesting. Expression of HA-
DAPK-1 and GFP-s-DAPK-1 was evaluated by immunoblotting. The non-specific band as shown in 























Figure 5.7 s-DAPK-1 stimulated DAPK-1 degradation is lysosome dependent. HEK293 cells were 
transfected with PCDNA3 (-) or the respective expression vectors as indicated, for 24h, in 
combination with chloroquine (lanes 3 and 5) treatments for 20h, prior to harvesting. Expression of 
HA-DAPK-1 and GFP-s-DAPK-1 was evaluated by immunoblotting. The non-specific band as shown 
in Figure 3.8 (A) was used as the loading control. This experiment has been performed more than 
3 times.  
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Chapter Six Discussion 
6.1 Result discussion 
As described in Chapter One, the role of cathepsin B in TNF- induced apoptosis is 
controversial and the mechanism through which TNF- kills the cells is still unclear. 
My observations may provide a new angle to investigate the function of cathepsin B 
in the TNFR-1-induced apoptotic pathways and demonstrate that DAPK-1 also needs 
to be considered. Interestingly, cathepsin B has long been known to be involved in 
cell malignancy. Tumour cells tend to have higher expression of cathepsin B, and the 
secretion of high levels of cathepsin B results in the degradation of cell extracellular 
matrices184. Moreover, it was reported that DAPK-1 can inhibit cell motility by 
blocking the integrin-mediated polarity pathway150. DAPK-1 is also reported to be 
highly expressed in invading tumour-associated macrophages in colorectal cancer, 
however DAPK-1 does not kill the cells185. The interaction between DAPK-1 and 
cathepsin B may shed light on explaining the dual function of both DAPK-1 and 
cathepsin B on the malignancy in tumours.  
 
As shown in Chapter Three (Figure 3.1), post-translational regulation is critical for 
the expression level of DAPK-1 protein. The result chapters demonstrate that DAPK-
1 can be degraded through both a cathepsin B-antagonized TNF- induced 
proteasomal degradation pathway and an s-DAPK-1 stimulated lysosomal 
degradation pathway. The mechanisms through which cathepsin B protects DAPK-1 
from TNF- induced degradation is still not clear. It has been reported that TNF- 
induces the degradation of the sphingosine kinase-1 (SK1) in a cathepsin B 
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dependent manner186. Interestingly, the authors showed that only the SK1 bound with 
motile cathepsin B released from leaking lysosomes get degraded, whilst the SK1 
around the contact lysosomes remained unprocessed186, suggesting that cathepsin B 
may not be a optimal protease for SK1 in the acidic environment in the lysosome. In 
contrast, cathepsin B may promote the degradation of DAPK-1 in the lysosome, 
while it becomes inactive as a DAPK-1 protease in the neutral environment in the 
cytosol. Thus when the proteasomal degradation pathway for DAPK-1 is activated 
by TNF-, the inactive cathepsin B acts to protect DAPK-1 from components of the 
proteasomal degradation pathway.  
 
Although cathepsin B is not responsible for the degradation of DAPK-1 in the 
context of my experiments and actually protects it from degradation, it may still 
promote DAPK-1 lysosomal degradation or cleave DAPK-1 under other 
environmental conditions. For example, it has been shown that in response to 2h of 
oxygen glucose deprivation, DAPK-1 is cleaved by cathepsin B in primary neuronal 
cells66, confirming that cathepsin B is able to degrade DAPK-1 in vivo under certain 
stresses or in specific cell types. Moreover, my results in chapter three also show that 
cathepsin B can interact and cleave DAPK-1 in vitro (Figure 3.5). Therefore, instead 
of being a negative regulator, cathepsin B may play a positive role in the s-DAPK-1 
stimulated lysosomal degradation pathway for DAPK-1. For example, cathepsin L is 
a highly redundant functional homologue of cathepsin B, and the mice with double 
knock-out of both cathepsin B and L have severe brain atrophy associated with 
selective neuronal loss in the cerebral cortex and in the cerebellar Purkinje and 
granule cell layers172, 187. Considering the apoptotic role of DAPK-1 in neuronal 
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death15 and that cathepsin B can cleave DAPK-1 protein, it raises the possibility that 
the neuronal loss in the cathepsin B and cathepsin L double knock-out mouse may be 
due to increased abundance of DAPK-1, further implicating a positive role of 
cathepsin B in regulating the degradation of DAPK-1.  
 
6.2 Degradation pathways for DAPK-1   
In addition to the data presented in the results chapters, there is some other work that 
I have done in collaboration with colleagues, mainly Dr. Craig Stevens, in the 
laboratory. We have identified another protein TSC2 (tuberous sclerosis 2) as a novel 
DAPK-1 death domain interacting protein that can mediate the degration of DAPK-1 
via both lysosome and proteaome dependent pathways (Unpublished data). 
Reciprocally, DAPK-1 can phosphorylate and inactivate TSC2, leading to the 
activation of the mTORC1 (mammalian target of rapamycin complex 1) signlling 
pathway, which is a major regulator of cell growth188.  
 
My own data along with other work from our laboratory clearly demonstrates the 
existence of an alternative lysosomal degradation pathway for DAPK-1 in addition to 
the existing ubiquitin-proteasome pathway. It is also clear that the steady state level 
of DAPK-1 is mainly controlled through this lysosomal pathway, and that both s-
DAPK-1 and TSC2 target DAPK-1 towards degradation through the lysosomal 
pathway. In contrast, upon cell treatment with stresses such as TNF- or Hsp90 




The TSC2 null mice and cathepsin B and L double knock-out mice die from distinct 
developmental defects and both TSC2 and cathepsin B are involved the regulation of 
DAPK-1 stability. If overexpression of DAPK-1 is responsible for the lethality of 
these mice, then in neuronal cells, cathepsin B is the major factor controlling DAPK-
1 degradation; while in liver cells, TSC2 is be the predominant regulator. Thus, the 
regulation of DAPK-1 is stability may vary dramatically in a tissue and cell-type 
specific manner.  
 
Taken together, several factors in the proteasomal and lysosomal degradation 
pathways for DAPK-1 have been discovered (Figure 6.1). However, unlike the 
proteasomal degradation pathway, not much is known about the mechanisms 
underlying the lysosomal degradation of DAPK-1, except the link between cathepsin 
B and the lysosome. Importantly, DAPK-1 is a positive regulator of IFN- induced 
autophagy15 and can induce autophagy when overexpressed25. The mechanism 
through which DAPK-1 induces autophagy is still not clear. Our data demonstrates 
that DAPK-1 can be degraded by the lysosome, thus it is possible that DAPK-1 can 
be sequestered into autophagolysosme and get degraded by atuophagy. Although 
more data is required, it may provide a potential mechanism for lysosome dependent 
degradation of DAPK-1.  
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6.3 Physiological role of DAPK-1   
The discovery that full activation of mTORC1 by EGF requires DAPK-1 indicates 
that DAPK-1 acts as a survival factor during EGF signalling. This is inconsistent 
with published data showing that in response to PMA, the DAPK-1-ERK complex 
induces apoptosis77. However, the apoptosis promoting effect of DAPK-1 induced by 
the ERK activator PMA was only observed in suspended cells77, and in the 
overexpression system, the constitutively active MEK signal is required for DAPK-1 
to induce apoptosis131. Therefore, the apoptosis function of the ERK-DAPK-1 
complex may only exist under aberrant conditions, such as when the growth signal is 
above the limit tolerated by cells. However, under physiological growth conditions, 
DAPK-1 acts as a survival factor, and promotes cell growth.  
 
As discussed in Section 1.9.1, Src may possess dual functions, and when the EGF 
signal is over the tolerated limit, Src directly phosphorylates and inactivates DAPK-1. 
This role of Src may make it a checkpoint in the cells to attenuate the growth signal 
when it starts to stress the cells. In the overexpression system, MEK/ERK/DAPK-1 
may bypass the limit that endogenous Src can cope with, which leads to apoptosis. 
As shown in Figure 6.5, sustained high levels of DAPK-1 are not tolerated by the 
cells. This supports the notion that active DAPK-1 is a positive regulator of cell 
growth, but during long-term culture, the growth signal induced by DAPK-1 must be 
restrained below a certain level, otherwise the cells will die. This is also consistent 
with the finding that long-term activation of the EGF pathway leads to cell death189. 
To investigate further the relationship between DAPK-1, Src and ERK in EGF 
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signalling pathway, a careful time and dose dependent titration of EGF in the 
presence and absence of DAPK-1 overexpression will be required.  
 
The data in chapter three confirmed that DAPK-1 can act as a survival factor in the 
TNF- signalling pathway. However, the mechanism underlying how DAPK-1 
antagonizes TNF- induced apoptosis and acts as a survival factor is still not clear. 
The discovery of the DAPK-1-TSC2 interaction may provide a clue. It has been 
shown that TNF- treatment induces phosphorylation of TSC1 at Ser487 and Ser511 
via IKK, leading to inactivation of the TSC complex and the subsequent 
angiogenesis and tumour development190. The ability of DAPK-1 to activate 
mTORC1 places DAPK-1 on the survival side of the TNF- pathway, and provides a 
mechanism to explain why DAPK-1 needs to be eliminated for cells to undergo 
apoptosis. Of note, the TNF- induced DAPK-1 degradation became obvious only 
after 2-4 hours of combined TNF- and CHX treatment151, whereas the mTORC1 
activation by TNF- was observed within 30 minutes of treatment190. Moreover, it 
was shown that in the early stage of TNF-/CHX treatment, the kinase activity of 
DAPK-1 is significantly increased, however this is not accompanied by changes in 
its protein level151. Therefore, it is possible that DAPK-1 activity is initially 
upregulated by TNF- to activate the mTORC1 pathway, and is then targeted for 
degradation at a later time when the apoptotic signal becomes dominant. Importantly, 
in most papers published about TNF-, the experiments were carried out in cells 
growing in serum containing medium, while in most papers on EGF, the experiments 
were performed in a serum free environment. It is possible that the anti-apoptotic 
effect of DAPK-1 in TNF- pathway is due to the activation of mTORC1 via 
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DAPK-1 by EGF in the medium. Extra caution is needed when trying to interpret the 
role of DAPK-1 in the TNF- and EGF pathways.  
 
6.4 Future perspectives 
As shown in chapter five, s-DAPK-1 can efficiently target DAPK-1 for degradation. 
It will be interesting to see whether s-DAPK-1 can facilitate TNFR-1 mediated 
DAPK-1 degradation similar to the 836-947 miniprotein. Moreover, in addition to 
CHX, a Smac mimetic can turn TNF- signalling towards apoptosis191. It will be 
interesting to see whether s-DAPK-1 or 836-847 miniprotein can further enhance 
apoptosis induced by TNF- in combination with CHX or Smac mimetic. If so, it 
may be worthwhile to map the minimal domain on the 836-947 miniprotein and the 
ankryrin repeat regions on DAPK-1, so that a potential drug-like peptide may be 
developed for future clinical trial.  
 
In addition, the TSC2 null mouse dies during embryonic development. Considering 
the tight connection between TSC2 and the expression level of DAPK-1, and the 
relation of DAPK-1 expression to cell death, it will be interesting to see whether 
knock-out of DAPK-1 can rescue the TSC2 null mouse from embryonic lethality. If 
so, it would provide a strong genetic link and physiological significance for the 
feedback loop between TSC2 and DAPK-1.  
 
In conclusion, my study has added s-DAPK-1, cathepsin B and TSC2 to the group of 
proteins that can regulate DAPK-1 stability (Figure 6.1). In addition, our discovery 
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that DAPK-1 acts as a survival factor suggests that under normal growth conditions, 
DAPK-1 may act as an oncogene. Given that the traditional notion of DAPK-1 as a 
tumour suppressor, and loss of DAPK-1 expression in some tumours leads to cancer, 
our study provides a new way of interpreting DAPK-1 expression in tumour cells. It 
also highlights the importance of studying the degradation control of DAPK-1. The 
observation that DAPK-1 expression is vital for some tumours to grow or resist 
certain stresses such as TNF-, may provide an important potential drug lead that 
can enhance the efficiency of current therapeutic strategies aimed at eliminating 










































Figure 6.1 Degradation pathways for DAPK-1. It has been published that DAPK-1 can be targeted 
for ubiquitin-proteasome degradation in response to TNF- and inhibition of Hsp90, the former of 
which may be induced by MIB1 and the latter is induced by MIB1 and CHIP. Moreover, our 
laboratory found that TSC2 can target DAPK-1 for both lysosomal and proteasomal degradation. In 
this work, I found that cathepsin B can inhibit the TNF- induced proteasomal degradation of DAPK-
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